High surface-area lyophilized compositions comprising arsenic for oral administration in patients

A lyophilized arsenic trioxide composition addresses the challenges of insolubility and low bioavailability in oral treatments by enhancing solubility and bioavailability, offering a convenient and effective oral treatment for hematological malignancies.

JP2024161468AActive Publication Date: 2024-11-19ケツァール·セラピューティクス·リミテッド·ライアビリティ·カンパニー
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
JP2024135193
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-04-03
Filing Date
2024-08-14
Publication Date
2024-11-19
Estimated Expiration
2036-02-01

AI Technical Summary

Technical Problem

Current arsenic trioxide treatments for hematological malignancies require daily intravenous administration, which is inconvenient, risky, and costly, with no approved oral formulations available, and existing oral formulations suffer from insolubility and low bioavailability.

Method used

Development of a lyophilized composition containing arsenic trioxide that is solubilized and lyophilized to enhance bioavailability, allowing for oral administration, with methods involving solubilization in an aqueous solvent, pH adjustment, surfactant addition, and freeze-drying to create a lyophilized powder suitable for capsules or tablets.

Benefits of technology

The lyophilized composition achieves systemic bioavailability comparable to intravenous administration, providing a convenient, less hazardous, and cost-effective treatment option with improved solubility and bioavailability, suitable for treating various hematological malignancies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161468000047
    Figure 2024161468000047
  • Figure 2024161468000048
    Figure 2024161468000048
  • Figure 2024161468000049
    Figure 2024161468000049
Patent Text Reader

Abstract

To address the issues of the insolubility of As2O3 and the lack of bioavailability and provide a lyophilized composition comprising arsenic that makes it bioavailable, and further to provide methods for production thereof, and methods for treating malignancies such as tumor or cancer by orally administering the lyophilized composition comprising arsenic.SOLUTION: A method for preparing a lyophilized composition comprising arsenic (LCCA) comprises the steps for: (A) solubilizing As2O3 powder in an aqueous medium to form an As2O3 solution; and (B) lyophilizing the As2O3 solution.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Application No. 62 / 110,574, filed February 1, 2015, and U.S. Provisional Application No. 62 / 142,709, filed April 3, 2015, which are incorporated herein by reference in their entireties.

[0002] FIELD OF THEINVENTION The present invention relates to treating malignancies, such as tumors or cancers, by administering to a subject a freeze-dried composition comprising arsenic. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML), including acute promyelocytic leukemia (APL), myelodysplastic syndromes (MDS), multiple myeloma (MM) and lymphoma; and solid tumors, including glioblastoma multiforme and breast cancer.

[0003] Conventional arsenic treatments, while showing great promise in the treatment of some cancers, require daily intravenous (IV) administration. In contrast, the oral formulation of the present invention provides systemic bioavailability comparable to currently practiced intravenous (IV) administration of arsenic trioxide. It also exhibits a shelf life of more than three months, providing a significantly more convenient, less risky, and less expensive method of administration of arsenic trioxide than that provided by intravenous administration methods. The present invention also relates to methods for producing lyophilized compositions comprising arsenic, methods for producing the oral formulations of the present invention, methods for orally administering the formulations to a subject, and methods for treating patients with malignancies, such as hematological malignancies, with the oral formulations. [Background technology]

[0004] Hematological malignancies Hematological malignancies are cancers of the body's blood system and immune system. Hematological malignancies include, for example, leukemia, lymphoma (both Hodgkin's disease and non-Hodgkin's lymphoma) and myeloma. Abnormal cell proliferation prevents the body from producing healthy blood cells, thus rendering the body unable to defend against infection.

[0005] New cases of hematologic malignancies account for approximately 9% of cancer cases diagnosed in the United States, and approximately 59,200 people die from the disease each year. Many of these diseases occur in children.

[0006] leukemia Leukemia is a cancer of the bone marrow and blood. It is characterized by the uncontrolled growth of blood cells. Approximately 30,000 new cases of leukemia are reported each year in the United States. Leukemia is the most common type of childhood cancer, although many cases occur in older adults.

[0007] Leukemias are either acute or chronic. In acute leukemia, the abnormal blood cells are blasts, which remain very immature and are unable to perform their normal functions. The number of blasts increases rapidly and the disease gets worse quickly. In chronic leukemia, some blast cells are present, but generally these cells are more mature and able to perform their normal functions. Also, the number of blasts increases less rapidly than in acute leukemia. As a result, chronic leukemia gets worse gradually.

[0008] Leukemia can occur in either of two main types: white blood cells-lymphoid cells (lymphocytic leukemia) or myeloid cells (myeloid leukemia). Common types of leukemia include acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML) (sometimes called acute nonlymphocytic leukemia (ANLL)), such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemic leukemia, acute neutrophilic leukemia, and myelodysplastic syndromes (MDS); chronic lymphocytic leukemia (CLL); chronic myelogenous (granulocytic) leukemia (CML); chronic myelomonocytic leukemia (CMML); hairy cell leukemia; and polycythemia vera and myeloproliferative neoplasms (including myelofibrosis polycythemia vera and essential thrombocythemia).

[0009] Lymphoma There are two main types of lymphoma - Hodgkin's disease and non-Hodgkin's lymphoma. Hodgkin's disease, also known as Hodgkin's lymphoma, is a special form of lymphoma that arises from certain cells known as Reed Sternberg (RS) cells, which are not usually found in other lymphomas.

[0010] The cause of Hodgkin's disease is unknown. Hodgkin's disease, like other cancers, is not contagious and cannot be passed on to others. It is not inherited. The first symptom of Hodgkin's disease is usually a painless swelling in the neck, armpits or groin. Other symptoms may include night sweats or unexplained fever, weight loss and fatigue, cough or shortness of breath, and persistent itching all over the body.

[0011] There are about 20 different types of non-Hodgkin's lymphoma. Non-Hodgkin's lymphomas are classified according to their appearance under a microscope and cell type (B-cell or T-cell). Risk factors include older age, female sex, weakened immune systems, human T-lymphotropic virus type 1 (HTLV-1) and Epstein-Barr virus infections, and exposure to chemicals such as pesticides, solvents, and fertilizers.

[0012] Myeloma Myeloma is a malignant tumor made up of plasma cells of the type normally found in bone marrow. Myeloma cells tend to collect in the bone marrow and the hard outer parts of bones. Sometimes they collect in just one bone, forming a single mass, or tumor, called a plasmacytoma. Often, however, myeloma cells collect in many bones, which often results in the formation of many tumors and other problems. When this occurs, the disease is called multiple myeloma, including, but not limited to, giant cell myeloma, asymptomatic myeloma, localized myeloma, multiple myeloma, plasma cell myeloma, sclerosing myeloma, solitary myeloma, smoldering multiple myeloma, nonsecretory myeloma, osteosclerosing myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma.

[0013] Myelodysplastic syndromes Myelodysplastic syndromes are disorders in which the bone marrow produces one or more types of cells (white blood cells, red blood cells, or platelets) that appear ineffective and abnormal. The majority of patients are men over 60 years of age. Secondary myelodysplastic syndromes are seen after the use of chemotherapy and radiation therapy.

[0014] The signs and symptoms depend on the type of cells affected: abnormal white blood cells make people more vulnerable to infections, abnormal platelets make people more vulnerable to internal and spontaneous bleeding, and abnormal red blood cells cause anemia and fatigue.

[0015] Although chemotherapy and radiation are useful in the treatment of hematological malignancies, there is a continuing need for better treatment modalities and more effective, less toxic approaches to managing the disease, especially as clinical oncologists pay more attention to the quality of life of cancer patients. The present invention provides an alternative approach to hematological malignancies treatment and disease management by using oral compositions containing arsenic trioxide.

[0016] Arsenic Arsenic has been used in medicine for over 2000 years. In the 18th century, a 1% w / v solution of arsenic trioxide (formula As2O3) in potassium bicarbonate (Fowler's solution) was developed to treat a variety of infectious and malignant diseases. Its effectiveness in suppressing white blood cells was first described in 1878 (Kwong YL et al. Delicious poison: arsenic trioxide for the treatment of leukemia, Blood 1997;89:3487-8). Thus, arsenic trioxide was used to treat chronic myeloid leukemia until more potent drugs replaced it in the 1940s. However, interest in such treatment was revived when arsenic trioxide was found to induce apoptosis and differentiation in acute promyelocytic leukemia (APL) cells (Chen GQ et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3exerts dose-dependent dual effect on APL cells in vitro and in vivo, Blood 1997;89:3345-53; Soignet SL et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-60).The clinical relevance of these in vitro observations has since been confirmed, as arsenic trioxide induces remission in more than 90% of such patients (Shen ZX et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood 1997;89:3354-60; Soignet SL et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med 1998;339:1341-8; Niu C. et al., Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood 1999;94:3315-24).

[0017] A typical course of arsenic trioxide involves daily intravenous (IV) administration for 4-8 weeks, with the inconvenience, risks, and costs of maintaining adequate vascular access and prolonged hospitalization. Currently, there is no oral arsenic trioxide approved by the FDA for clinical use. Fowler's solution is no longer detailed in the Modern Pharmacopoeia or listed in the compendium (1941, Arsenum. Martindale, The Extra Pharmacopoeia 22:209-15; British Pharmacopoeia. London: Her Majesty's Stationery Office, 1988; Appendix 1A, p A12). Thus, an arsenic-containing formulation that could be administered orally could offer a distinct advantage.

[0018] The present inventors have arrived at a novel formulation comprising a freeze-dried composition comprising arsenic that can be administered orally. The present inventors have developed a method for making the novel formulation comprising a freeze-dried composition comprising arsenic. The freeze-dried powder comprising arsenic is suitable for oral administration in patients, for example, by capsules and tablets.

[0019] As2O3 powder is practically insoluble in cold water and dissolves slowly; even in boiling water it dissolves only in a ratio of 1:15 (Arsenic Trioxide, In: Budavari S O'Neil MJ (Eds), The Merck Index. An encyclopedia of chemicals, drugs and biologicals. NJ: Merck & Co., Inc. 11th Ed., Rahway, NJ, USA. 1989. Monograph 832, p 127). As a result, and because of the other problems mentioned above, it has not been formulated as an orally available composition. Summary of the Invention

[0020] The present invention addresses the problem of insolubility and lack of bioavailability of As2O3 by providing a freeze-dried composition containing arsenic that is bioavailable. The arsenic is introduced as As2O3 powder, which is then solubilized and freeze-dried as described below. More specifically, the present invention relates to a freeze-dried composition containing arsenic, where the arsenic is present as one or more arsenic salts, and / or solvates thereof, and / or As2O3, and / or one or more arsenic compounds.

[0021] Thus, a "lyophilized composition containing arsenic" (LCCA) as used herein means a composition containing arsenic as one or more salts thereof, and / or solvates thereof, and / or arsenic trioxide and / or other compounds containing arsenic, which composition is obtained by applying the method steps of the invention as described below. Alternatively, a lyophilized composition containing arsenic may be referred to herein as lyophilized arsenic trioxide or lyophilized As2O3 (LAT).

[0022] Obviously, the present invention contemplates making this "lyophilized composition containing arsenic" by other methods.

[0023] In other words, a lyophilized composition comprising an independent arsenic is an aspect of the present invention. In one aspect, the present invention also relates to a method of making an LCCA. In another aspect, the present invention also relates to an oral formulation comprising an LCCA. In yet another aspect, the present invention also relates to a method of making said oral formulation. The present invention also relates to a pharmaceutical composition in solid dosage form suitable for oral administration, comprising a lyophilized composition comprising arsenic. The present invention further relates to a pharmaceutical composition in solid dosage form suitable for oral administration, comprising an LCCA, at least one filler and at least one lubricant. In one aspect, the present invention also relates to a kit comprising a pharmaceutical composition comprising an LCCA. In yet another aspect, the present invention also relates to a method of treating a malignancy, e.g., a hematological malignancy, in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising an LCCA.

[0024] EMBODIMENTS - METHOD OF MAKING A FREEZE-DRIED COMPOSITION COMPRISING ARSENIC The present invention relates to a method for producing a freeze-dried composition (LCCA) containing arsenic, comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; and (B) freeze-drying the As2O3 solution. In one embodiment, the step of solubilizing the As2O3 powder in an aqueous solvent comprises: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without adding water to achieve a pH of about 12 or higher; (II) adding an acid to the vessel with or without stirring and with or without adding water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without adding water, and (IV) optionally adding water to the vessel with or without stirring to generate an As2O3 solution. In another embodiment, for the method described above in this section, the alkalizing agent comprises sodium hydroxide (NaOH), sodium carbonate (Na2CO3), or a mixture thereof. In yet another embodiment, the amount of alkalizing agent added in the above method is about 10% to about 100% of the amount of As2O3 powder.

[0025] In one embodiment of the invention, for the method described above in this section, the acid comprises hydrochloric acid (HCl). In another embodiment, the HCl is about 6M HCl. In a further embodiment, the acid is added to the vessel to adjust the pH to about 7.2. In yet another embodiment, for the method described above in this section, the surfactant comprises at least one of sodium lauryl sulfate; Tween 80®; beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS). In another embodiment, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but does not exceed about 50% of the As2O3 concentration.

[0026] In yet another embodiment of the present invention, for the method described above in this section, the freeze-drying step comprises: (A) freezing the As2O3 solution to produce a frozen As2O3 product; and (B) drying the As2O3 product to produce a freeze-dried composition comprising arsenic. In another embodiment, for the method described above, the freezing step comprises freezing the As2O3 solution at a temperature ranging from about -50°C to about 0°C. In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours. In yet another embodiment, the drying step comprises at least one of three conditions: (I) drying the As2O3 product at at least one temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes; (II) drying the frozen As2O3 by gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes, where the at least one second temperature is higher than the at least one first temperature; and (III) applying a vacuum in the range of about 300 mTorr to about 1000 mTorr to the frozen As2O3 product for a time in the range of about 5 minutes to about 500 minutes.

[0027] In one embodiment of the invention, for the method described hereinabove in this section, the drying step includes heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step at about 25°C and about 500 mTorr for a time ranging from about 180 minutes to about 300 minutes. In yet another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr over about 60 minutes, and then holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

[0028] EMBODIMENT - FREEZE-DRIED COMPOSITION COMPRISING ARSENIC The present invention relates to a composition comprising lyophilized composition (LCCA) containing arsenic.In one embodiment, the composition further comprises at least one filler and at least one lubricant.In another embodiment, the composition is produced by a method comprising the steps of: (A) solubilizing As2O3 powder in aqueous solvent to form As2O3 solution; (B) freeze-drying the As2O3 solution to produce lyopremix; (C) sieving the lyopremix to produce lyopremix As2O3 powder; (D) optionally adding at least one filler to the lyopremix As2O3 powder; (E) optionally adding one or more lubricants to the lyopremix As2O3 powder to produce the oral formulation of As2O3.

[0029] In one embodiment of the present invention, for the composition, the step of solubilizing the As2O3 powder in an aqueous solvent includes: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without the addition of water to a pH of about 12 or higher; (II) adding an acid to the vessel with or without stirring and with or without the addition of water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without the addition of water, and (IV) optionally adding water to the vessel with or without stirring to generate an As2O3 solution. In another embodiment, for the composition described above, the alkalizing agent includes sodium hydroxide (NaOH), sodium carbonate (Na2CO3), or a mixture thereof. In yet another embodiment, the amount of the alkalizing agent added in the above composition is about 10% to about 100% of the amount of As2O3 powder.

[0030] In one embodiment of the invention, for the composition described above, the acid comprises hydrochloric acid (HCl). In another embodiment, the HCl is about 6M HCl. In a further embodiment, the acid is added to the vessel to adjust the pH to about 7.2. In yet another embodiment, for the composition described above, the surfactant comprises at least one of sodium lauryl sulfate; Tween 80®; beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS). In another embodiment, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but does not exceed about 50% of the As2O3 concentration.

[0031] In yet another embodiment of the present invention, for the above composition, the freeze-drying step comprises: (A) freezing the As2O3 solution to produce a frozen As2O3 product; and (B) drying the As2O3 product to produce a freeze-dried composition containing arsenic. In another embodiment, for the compositions described above, the freezing step comprises freezing the As2O3 solution at a temperature ranging from about -50°C to about 0°C. In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours. In yet another embodiment, the drying step comprises at least one of three conditions: (I) drying the As2O3 product at at least one temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes; (II) drying the frozen As2O3 by gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes, where the at least one second temperature is higher than the at least one first temperature; and (III) applying a vacuum in the range of about 300 mTorr to about 1000 mTorr to the frozen As2O3 product for a time in the range of about 5 minutes to about 500 minutes.

[0032] In one embodiment of the invention, for the compositions described hereinbefore in this section, the drying step comprises heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step at about 25°C and about 500 mTorr for a time ranging from about 180 minutes to about 300 minutes. In yet another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr over about 60 minutes, and then holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

[0033] In another embodiment of the present invention, for the compositions described above in this section, the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.In another embodiment, the compositions are controlled release, oral, solid, compositions.In one embodiment, the compositions described above in this section are encapsulated.

[0034] EMBODIMENT - METHOD FOR MANUFACTURING ORAL PHARMACEUTICAL FORMULATIONS COMPRISING LCCA The present invention relates to a method for producing an oral pharmaceutical formulation comprising a lyophilized composition comprising arsenic or lyophilized arsenic trioxide (As2O3), comprising the steps of: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; (B) lyophilizing the As2O3 solution to produce a lyopremix; (C) sieving the lyopremix to produce a lyophilized As2O3 powder; (D) optionally adding at least one bulking agent to the lyophilized As2O3 powder; and (E) optionally adding one or more lubricants to the lyophilized As2O3 powder to produce an oral formulation of As2O3.

[0035] The present invention also relates to the method, wherein the step of solubilizing the As2O3 powder in an aqueous solvent comprises: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without the addition of water to a pH of about 12 or more; (II) adding an acid to the vessel with or without stirring and with or without the addition of water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without the addition of water, and (IV) optionally adding water to the vessel with or without stirring to generate an As2O3 solution. In another embodiment, for the method described above in this section, the alkalizing agent comprises sodium hydroxide (NaOH), sodium carbonate (Na2CO3), or a mixture thereof. In yet another embodiment, the amount of the alkalizing agent added in the above method is about 10% to about 100% of the amount of the As2O3 powder.

[0036] In one embodiment of the invention, for the method described above in this section, the acid comprises hydrochloric acid (HCl). In another embodiment, the HCl is about 6M HCl. In a further embodiment, the acid is added to the vessel to adjust the pH to about 7.2. In yet another embodiment, for the method described above in this section, the surfactant comprises at least one of sodium lauryl sulfate; Tween 80®; beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS). In another embodiment, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but does not exceed about 50% of the As2O3 concentration.

[0037] In yet another embodiment of the present invention, for the method described above in this section, the freeze-drying step comprises: (A) freezing the As2O3 solution to produce a frozen As2O3 product; and (B) drying the As2O3 product to produce a freeze-dried composition comprising the arsenic. In another embodiment, for the method described above, the freezing step comprises freezing the As2O3 solution at a temperature ranging from about -50°C to about 0°C. In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours. In yet another embodiment, the drying step comprises at least one of three conditions: (I) drying the As2O3 product at at least one temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes; (II) drying the frozen As2O3 by gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes, where the at least one second temperature is higher than the at least one first temperature; and (III) applying a vacuum in the range of about 300 mTorr to about 1000 mTorr to the frozen As2O3 product for a time in the range of about 5 minutes to about 500 minutes.

[0038] In one embodiment of the invention, for the method described hereinabove in this section, the drying step includes heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step at about 25°C and about 500 mTorr for a time ranging from about 180 minutes to about 300 minutes. In yet another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr over about 60 minutes, and then holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

[0039] In another embodiment of the present invention, for the method as described above in this section, the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate. In another embodiment, the method as described above further comprises the step of filling the oral formulation into a capsule.

[0040] EMBODIMENT - Oral pharmaceutical formulation containing LCCA The present invention relates to a pharmaceutical composition in solid dosage form suitable for oral administration, comprising a lyophilized composition comprising arsenic.In one embodiment, the pharmaceutical composition further comprises at least one filler and at least one lubricant.In yet another embodiment, the pharmaceutical composition described above in this section is produced by a method comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; (B) lyophilizing the As2O3 solution to produce a lyopremix; (C) sieving the lyopremix to produce a lyopremix powder; (D) optionally adding at least one filler to the lyopremix powder; (E) optionally adding one or more lubricants to the lyopremix powder to produce the oral formulation of As2O3.

[0041] In one embodiment of the present invention, for the pharmaceutical compositions described above in this section, the step of solubilizing the As2O3 powder in an aqueous solvent comprises: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without the addition of water to a pH of about 12 or higher; (II) adding an acid to the vessel with or without stirring and with or without the addition of water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without the addition of water, and (IV) optionally adding water to the vessel with or without stirring to generate an As2O3 solution. In another embodiment, for the compositions described above, the alkalizing agent comprises sodium hydroxide (NaOH), sodium carbonate (Na2CO3), or a mixture thereof. In yet another embodiment, the amount of the alkalizing agent added in the pharmaceutical compositions described above is about 10% to about 100% of the amount of the As2O3 powder.

[0042] In one embodiment of the invention, for the pharmaceutical composition described above, the acid comprises hydrochloric acid (HCl). In another embodiment, the HCl is about 6M HCl. In a further embodiment, the acid is added to the vessel to adjust the pH to about 7.2. In yet another embodiment, for the pharmaceutical composition described above, the surfactant comprises at least one of sodium lauryl sulfate; Tween 80®; beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS). In another embodiment, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but does not exceed about 50% of the As2O3 concentration.

[0043] In yet another embodiment of the present invention, for the pharmaceutical composition described above, the freeze-drying step comprises: (A) freezing the As2O3 solution to produce a frozen As2O3 product; and (B) drying the As2O3 product to produce a freeze-dried composition comprising the arsenic. In another embodiment, for the composition described above, the freezing step comprises freezing the As2O3 solution at a temperature ranging from about -50°C to about 0°C. In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours. In yet another embodiment, the drying step comprises at least one of three conditions: (I) drying the As2O3 product at at least one temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes; (II) drying the frozen As2O3 by gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time in the range of about 5 minutes to about 500 minutes, where the at least one second temperature is higher than the at least one first temperature; and (III) applying a vacuum in the range of about 300 mTorr to about 1000 mTorr to the frozen As2O3 product for a time in the range of about 5 minutes to about 500 minutes.

[0044] In one embodiment of the invention, for the pharmaceutical compositions described hereinabove, the drying step comprises heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step at about 25°C and about 500 mTorr for a time ranging from about 180 minutes to about 300 minutes. In yet another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product from the previous step to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product from the previous step to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product from the previous step to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr over about 60 minutes, and then holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

[0045] In another embodiment of the present invention, for the pharmaceutical composition described above in this section, the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.In another embodiment, the pharmaceutical composition is a controlled release, oral, solid, composition.In one embodiment, the pharmaceutical composition described above in this section is encapsulated.

[0046] In another set of embodiments, the invention also relates to a capsule containing about 1 mg, about 5 mg, 10 mg, or about 20 mg of a pharmaceutical composition as described in this section.The invention further relates to a kit comprising a pharmaceutical composition as described in this section and instructions for its use.

[0047] EMBODIMENTS - ADMINISTRATION OF PHARMACEUTICAL COMPOSITION TO A PATIENT The present invention relates to a method of orally administering to a subject a pharmaceutical composition comprising a lyophilized composition comprising arsenic, comprising the steps of providing the pharmaceutical composition and orally administering the composition to the subject.The present invention further relates to a method of treating a malignancy, such as a cancer or tumor, in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a lyophilized composition comprising arsenic.

[0048] In yet another embodiment, the present invention relates to the method described above in this section, wherein said cancer is a hematopoietic malignancy. In another embodiment, the hematopoietic malignancy is at least one of acute myeloid leukemia; acute nonlymphocytic leukemia; myeloblastic leukemia, promyelocytic leukemia; chronic myelomonocytic leukemia; monocytic leukemia; erythroleukemia; acute neutrophilic leukemia; myelodysplastic syndrome; acute promyelocytic leukemia; chronic lymphocytic leukemia; chronic myelogenous leukemia; hairy cell leukemia; myeloproliferative neoplasms; Hodgkin's lymphoma; non-Hodgkin's lymphoma; myeloma; giant cell myeloma; indolent myeloma; localized myeloma; multiple myeloma; plasma cell myeloma; sclerosing myeloma; solitary myeloma; smoldering multiple myeloma; nonsecretory myeloma; osteosclerosing myeloma; plasma cell leukemia; solitary plasmacytoma; and extramedullary plasmacytoma.

[0049] In another embodiment, for the method described above in this section, said hematopoietic tumor is acute promyelocytic leukemia (APL).In one embodiment, said APL is newly diagnosed APL.In another embodiment, said APL is relapsed or refractory APL.

[0050] In one embodiment, in the methods of treatment described above in this section, the myeloproliferative neoplasm is one of myelofibrosis polycythemia vera and essential thrombocythemia.

[0051] In one embodiment of the present invention, for the methods described in this section, the pharmaceutical composition is administered daily. In another embodiment, the pharmaceutical composition is administered in a single dose ranging from about 1 mg to about 50 mg. In a further embodiment, the pharmaceutical composition is administered in a single dose ranging from about 0.1 mg / kg body weight to about 0.3 mg / kg body weight.

[0052] In another embodiment, for the method described above in this section, the patient has been previously treated or is currently treated with chemotherapy and / or radiation.In another embodiment, the patient is further administered one or more chemotherapeutic agents.In one embodiment of this method, the chemotherapeutic agent is administered before, after or simultaneously with the pharmaceutical composition.

[0053] EMBODIMENTS - IMPROVING PHYSICAL / CHEMICAL PROPERTIES OF FORMULATION POWDERS The present invention relates to a method for increasing the surface area of ​​an original API powder comprising arsenic trioxide by about 2-fold to about 80-fold, comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution, comprising: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without added water to achieve a pH of about 12 or greater; (II) adding an acid to the vessel with or without stirring and with or without added water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without added water, and (IV) optionally adding water to the vessel with or without stirring to produce an As2O3 solution; and (B) lyophilizing the As2O3 solution, comprising: (V) freezing the As2O3 solution to produce a frozen As2O3 product; and (VI) drying the As2O3 product to produce a lyophilized composition comprising the arsenic.

[0054] The present invention also relates to a method for increasing the solubility of arsenic trioxide powder in water or alcohol by about 2-fold to about 30-fold, comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution, comprising: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without added water to achieve a pH of about 12 or greater; (II) adding an acid to the vessel with or without stirring and with or without added water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without added water, and (IV) optionally adding water to the vessel with or without stirring to produce an As2O3 solution; and (B) lyophilizing the As2O3 solution, comprising: (V) freezing the As2O3 solution to produce a frozen As2O3 product; and (VI) drying the As2O3 product to produce a lyophilized composition comprising the arsenic.

[0055] The present invention also relates to a method for increasing the dissolution of a pharmaceutical composition comprising arsenic by at least 5-fold over the parent API comprising arsenic trioxide, comprising the steps of: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution, comprising: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without added water to achieve a pH of about 12 or higher; (II) adding an acid to the vessel with or without stirring and with or without added water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without added water, and (IV) optionally adding water to the vessel with or without stirring to produce an As2O3 solution; and (B) lyophilizing the As2O3 solution, comprising: (V) freezing the As2O3 solution to produce a frozen As2O3 product; and (VI) drying the As2O3 product to produce a lyophilized composition comprising the arsenic.

[0056] The present invention also provides a method for providing oral bioavailability of arsenic to a subject ranging from about 50% to about 100% of the bioavailability of intravenously administered pharmaceutical compositions comprising arsenic, comprising the steps of: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution, comprising: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without added water to achieve a pH of about 12 or greater; (II) adding an acid to the vessel with or without stirring and with or without added water to achieve a pH of about 12 or greater; (III) optionally adding a surfactant to the vessel with or without stirring and with or without the addition of water, and (IV) optionally adding water to the vessel with or without stirring to produce an As2O3 solution; and (B) lyophilizing the As2O3 solution, comprising: (V) freezing the As2O3 solution to produce a frozen As2O3 product; and (VI) drying the As2O3 product to produce a lyophilized composition comprising arsenic.

[0057] The present invention also relates to a composition comprising a lyophilized composition containing arsenic (LCCA), the lyophilized composition containing arsenic comprising particles with a D(90) size range of about 2 μm to 10 μm. In another embodiment, the lyophilized composition containing arsenic comprises particles having a D(90) size range of about 10 to about 50 times smaller than the particle size of the original API powder containing arsenic trioxide. In yet another embodiment, the lyophilized composition containing arsenic comprises particles having a D(90) size range of about 0.5 μm to about 10 μm. 2 / g~5m 2In another embodiment, the lyophilized composition comprising arsenic comprises particles having a BET surface area in the range of about 5 to about 80 times greater than the surface area of ​​the original API powder comprising arsenic trioxide. In another embodiment, the lyophilized composition comprising arsenic is about 2 to about 30 times more soluble in cold water or alcohol than the original API powder comprising arsenic trioxide. In another embodiment, the lyophilized composition comprising arsenic is soluble in cold water or alcohol in the range of about 4 g / 100 g to about 60 g / 100 g of the lyophilized composition per 100 g of cold water or alcohol.

[0058] In one embodiment, the present invention relates to a pharmaceutical composition as described in the previous section, wherein the dissolution of the pharmaceutical composition is about 5-fold to about 15-fold that of the original API powder containing arsenic trioxide as measured by ICP-OES.

[0059] The present invention also relates to an oral dosage form in the form of a capsule, weighing 100 units; bringing the total weight of the composition to 100 units, comprising: (I) a lyophilized composition comprising arsenic in an amount providing 10 units of arsenic trioxide and 5 units of sodium lauryl sulfate; (II) mannitol in an amount of 73 units; (III) talc in an amount of 1; and (IV) magnesium stearate in an amount of 1 mg. In one set of embodiments of the present invention, the capsule weighs 10 mg, 50 mg, 100 mg or 200 mg.

[0060] For example, weighing 10 mg, bringing the total weight of the composition to 10 mg: (I) a lyophilized composition comprising arsenic in an amount to provide 1 mg of arsenic trioxide and 0.5 mg of sodium lauryl sulfate; (II) mannitol in an amount of 7.3 mg; (III) talc in an amount of 0.1 mg; and (IV) magnesium stearate in an amount of 0.1 mg 16. An oral dosage form in the form of a capsule comprising: Similarly, weighing 50 mg, bringing the total weight of the composition to 50 mg: (I) a lyophilized composition comprising arsenic in an amount to provide 5 mg of arsenic trioxide and 2.5 mg of sodium lauryl sulfate; (II) mannitol in an amount of 36.5 mg; (III) talc in an amount of 0.5 mg; and (IV) magnesium stearate in an amount of 0.5 mg 16. An oral dosage form in the form of a capsule comprising:

[0061] In another example, the weight is 100 mg, bringing the total weight of the composition to 100 mg: (I) a lyophilized composition comprising arsenic in an amount to provide 10 mg of arsenic trioxide and 5 mg of sodium lauryl sulfate; (II) mannitol in an amount of 73 mg; (III) talc in an amount of 1 mg; and (IV) magnesium stearate in an amount of 1 mg 16. An oral dosage form in the form of a capsule comprising:

[0062] In another example, the weight is 200 mg, bringing the total weight of the composition to 200 mg: (I) a lyophilized composition comprising arsenic in an amount to provide 20 mg of arsenic trioxide and 10 mg of sodium lauryl sulfate; (II) mannitol in an amount of 146 mg; (III) talc in an amount of 2 mg; and (IV) magnesium stearate in an amount of 2 mg 16. An oral dosage form in the form of a capsule comprising:

[0063] These and other aspects of the invention are described in detail below. [Brief description of the drawings]

[0064] [Figure 1] FIG. 1 shows the pharmacokinetic analysis in dogs of a novel lyophilized formulation containing arsenic and a comparison with the control arsenic trioxide.

[0065] [Diagram 2] FIG. 2 shows a manufacturing flow diagram for freeze-drying and capsule production.

[0066] [Diagram 3] FIG. 3 shows the X-ray diffraction for arsenic trioxide (API).

[0067] [Figure 4] FIG. 4 shows the X-ray diffraction of the lyopremix, a freeze-dried composition containing arsenic.

[0068] [Diagram 5] FIG. 5 shows the X-ray diffraction for the final mixture (pharmaceutical formulation) containing the lyophilized composition containing arsenic.

[0069] [Figure 6] FIG. 6 shows the X-ray diffraction for the placebo.

[0070] [Figure 7] FIG. 7 shows SEM images of arsenic trioxide API; lyopremix; and the final mixture.

[0071] [Figure 8] FIG. 8 provides a BET surface area plot for arsenic trioxide API, which shows how 1 / [Q(Po / P-1)] depends on the relative pressure P / Po.

[0072] [Figure 9] FIG. 9 provides a BET surface area plot for Lyopremix (a freeze-dried composition containing arsenic), which shows how 1 / [Q(Po / P-1)] depends on the relative pressure P / Po. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0073] The present invention relates to a method for preparing a freeze-dried composition (LCCA) containing arsenic, comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; and (B) freeze-drying the As2O3 solution. In one embodiment, the solubilizing As2O3 powder in an aqueous solvent comprises: (I) adding an alkalizing agent to the As2O3 powder in a vessel with or without stirring and with or without adding water to adjust the pH to about 12 or higher; (II) adding an acid to the vessel with or without stirring and with or without adding water to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel with or without stirring and with or without adding water, and (IV) optionally adding water to the vessel with or without stirring to generate an As2O3 solution.

[0074] In yet another embodiment of the present invention, the method described above in this section, the freeze-drying step comprises: (A) freezing the As2O3 solution to produce a frozen As2O3 product; and (B) drying the As2O3 product to produce a freeze-dried composition comprising the arsenic. In another embodiment, for the method described above, the freezing step comprises freezing the As2O3 solution at a temperature ranging from about -50°C to about 0°C. In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours.

[0075] The present invention also relates to a composition comprising lyophilized composition (LCCA) containing arsenic.In one embodiment, the composition further comprises at least one filler and at least one lubricant.In another embodiment, the composition is produced by a method comprising the steps of: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; (B) freeze-drying the As2O3 solution to produce a lyopremix; (C) sieving the lyopremix to produce a lyopremix powder; (D) optionally adding at least one filler to the lyopremix powder; (E) optionally adding one or more lubricants to the lyopremix powder to produce an oral formulation of As2O3.

[0076] In another embodiment of the present invention, for the compositions described above in this section, the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.In another embodiment, the compositions are controlled release, oral, solid, compositions.In one embodiment, the compositions described above in this section are encapsulated.

[0077] The present invention also relates to a method for preparing an oral pharmaceutical formulation comprising a freeze-dried composition comprising arsenic or freeze-dried arsenic trioxide (As2O3), comprising: (A) solubilizing As2O3 powder in an aqueous solvent to form an As2O3 solution; (B) freeze-drying the As2O3 solution to produce a lyopremix; (C) sieving the lyopremix to produce a freeze-dried As2O3 powder; (D) optionally adding at least one filler to the freeze-dried As2O3 powder; (E) optionally adding one or more lubricants to the freeze-dried As2O3 powder to produce an oral formulation of As2O3. The present invention relates to a pharmaceutical composition in a solid dosage form suitable for oral administration, comprising a freeze-dried composition comprising arsenic. In one embodiment, the pharmaceutical composition further comprises at least one filler and at least one lubricant. In yet another embodiment, the pharmaceutical composition described above in this section is prepared by the method described herein. In another embodiment of the present invention, for the pharmaceutical composition described above in this section, the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.In another embodiment, the pharmaceutical composition is a controlled release, oral, solid, composition.In one embodiment, the pharmaceutical composition described above in this section is encapsulated.

[0078] In another set of embodiments, the invention also relates to a capsule containing about 1 mg, about 5 mg, 10 mg, or about 20 mg of a pharmaceutical composition as described in this section.The invention further relates to a kit comprising a pharmaceutical composition as described in this section and instructions for its use.

[0079] The present invention relates to a method of orally administering to a subject a pharmaceutical composition comprising a lyophilized composition comprising arsenic, the method comprising the steps of providing the pharmaceutical composition and orally administering the composition to the subject.The present invention further relates to a method of treating cancer in a patient in need of treatment, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a lyophilized composition comprising arsenic.

[0080] The present invention relates to methods for increasing the surface area of ​​an original API powder comprising arsenic trioxide by about 5-fold to about 80-fold; for increasing the solubility of arsenic trioxide powder in water or alcohol by about 2-fold to about 30-fold; for increasing the dissolution of a pharmaceutical composition comprising arsenic by at least 5-fold over the original API; for providing an oral bioavailability of arsenic to a subject that ranges from about 50% to about 100% of the bioavailability of intravenous administration of a pharmaceutical composition comprising arsenic; and for reducing the D(90) size of the particles to about 2 μm to about 10 μm.

[0081] The present invention also relates to an oral dosage form in the form of a capsule, weighing 100 units; bringing the total weight of the composition to 100 units, comprising: (I) a lyophilized composition comprising arsenic in an amount providing 10 units of arsenic trioxide and 5 units of sodium lauryl sulfate; (II) mannitol in an amount of 73 units; (III) talc in an amount of 1; and (IV) magnesium stearate in an amount of 1 mg. In one set of embodiments of the present invention, the capsule weighs 10 mg, 50 mg, 100 mg or 200 mg.

[0082] How to use Use in subjects with hematological malignancies The present invention further provides a method of using the lyophilized composition comprising arsenic administered orally. In one embodiment, the lyophilized composition comprising arsenic is used as a medicine for the treatment of hematological malignancies (e.g., leukemia, Hodgkin's disease, non-Hodgkin's lymphoma and myeloma). The method comprises administering to a subject in need thereof an effective amount of the lyophilized composition comprising arsenic. The lyophilized composition comprising arsenic may be administered orally in lyophilized form or enterally via nutrition. As used herein, the term "effective amount" refers to an amount sufficient to provide a therapeutic or health benefit in the context of hematological malignancies.

[0083] In one embodiment, the lyophilized composition comprising arsenic can produce health benefits in subjects suffering from hematological malignancies. Preferably, the subject is a human. The subject in need is a subject diagnosed with hematological malignancies at any stage of the disease, with or without metastasis. The term "hematological malignancies" as used herein includes, but is not limited to, leukemia, lymphoma, and myeloma. The term "leukemia" as used herein includes, but is not limited to, acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML) (sometimes referred to as acute non-lymphocytic leukemia (ANLL)), such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemic leukemia, and myelodysplastic syndrome; chronic lymphocytic leukemia (CLL); chronic myelogenous (granulocytic) leukemia (CML); chronic myelomonocytic leukemia (CMML); hairy cell leukemia; and polycythemia vera. The term "lymphoma" as used herein includes, but is not limited to, Hodgkin's disease and non-Hodgkin's lymphoma. The term "myeloma" as used herein includes, but is not limited to, giant cell myeloma, indolent myeloma, localized myeloma, multiple myeloma, plasma cell myeloma, sclerosing myeloma, solitary myeloma, smoldering multiple myeloma, nonsecretory myeloma, osteosclerosing myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma.

[0084] The subject may be a patient who is concurrently receiving other therapies for hematological malignancies. The subject may be a patient with hematological malignancies who has undergone a treatment regimen (e.g., chemotherapy and / or radiation) and whose cancer has regressed. The subject may be a patient with hematological malignancies who has undergone a treatment regimen and whose cancer does not appear to be a hematological malignancy clinically. The lyophilized composition comprising arsenic of the present invention may be orally administered adjunctively with any treatment regimen (e.g., including but not limited to chemotherapy and / or radiation). For example, the arsenic trioxide composition may be administered in combination with one or more chemotherapeutic or immunotherapeutic agents, such as amsacrine (AMSA), busulfan (Myleran®), chlorambucil (Leukeran®), cladribine (2-chlorodeoxyadenosine; "2-CDA"; Leustatin®), cyclophosphamide (Cytoxan®), cytarabine (ara-C; Cytosar-U®), daunorubicin (Cerubidine®), doxorubicin (Adriamycin®), etoposide (VePesid®), fludarabine phosphate (Fludara®), hydroxyurea (Hydrea®), idarubicin (Idamycin®), L-asparagine, or the like. Arsenic trioxide compositions may be used in combination with arsenic trioxide (Elspar®), methotrexate sodium plus 6-mercaptopurine (6-MP; Purinethol®), mitoxantrone (Novantrone®), pentostatin (2-deoxycoformycin; "DCF"; Nipent®), prednisone, retinoic acid (ATRA), vincristine sulfate (Oncovin®), 6-thioguanine (Tabloid®), cyclosporine A, Taxol®), Cisplatin®, Carboplatin®, Doxil®, Topotecan®, Methotrexate®, Bleomycin®, and Epirubicin®. Arsenic trioxide compositions may also be used after other treatment regimens have been administered.

[0085] The subject may be one who has not yet been diagnosed with a hematological malignancy, but who is predisposed to or at high risk of developing a hematological malignancy as a result of genetic and / or environmental factors.

[0086] Depending on the subject, therapeutic and health benefits range from preventing the growth of hematological malignancies and / or the spread of hematological malignancies to other parts of the body (i.e., metastasis), alleviating cancer symptoms, improving survival rates for cancer patients, increasing the subject's life expectancy, improving the subject's quality of life, and / or reducing the likelihood of recurrence after a successful course of treatment (e.g., chemotherapy, radiation). Symptoms associated with hematological malignancies include, but are not limited to, a weakened immune system, infections, fever, reduced red blood cells and platelets, weakness, fatigue, loss of appetite, weight loss, enlarged or tender lymph nodes, liver or pancreas, easy bleeding or bruising, small red spots under the skin (called petechiae), swollen or bleeding gums, sweating (especially at night), bone or joint pain, headaches, vomiting, confusion, loss of muscle control, and seizures.

[0087] In particular, the present invention provides a method for complete remission of hematological malignancies in a subject, e.g., a human, comprising orally administering to the subject an arsenic trioxide composition of the present invention. In other embodiments, the present invention provides at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 95% remission of hematological malignancies. The present invention also provides a method for extending the survival time of a subject, preferably a human patient, afflicted with a hematological malignancy, comprising orally administering to the subject an arsenic-containing lyophilized composition of the present invention.

[0088] Effective dose varies with the subject being treated and the route of administration. Effective dose for a subject also varies with the condition being treated and the severity of the condition being treated. Dose, and perhaps dose frequency, also varies with age, weight and response of individual subjects. In general, the total daily dosage range of lyophilized composition containing arsenic for subjects suffering from hematological malignancies in mg is as follows: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50 mg / day. Depending on the patient's needs, it can be higher, such as 60, 70, 80, 90 and 100 mg / day, or any intermediate dose number in between. The lyophilized premix containing the arsenic composition is administered orally to the subject.

[0089] The length of time of the treatment course should be at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 7 weeks, at least 10 weeks, at least 13 weeks, at least 15 weeks, at least 20 weeks, at least 6 months, at least 1 year, or at least 2 years.As will be clear to those skilled in the art, it may be necessary to use doses outside these ranges in some cases.In certain embodiments, the lyophilized composition containing arsenic can be administered for a period of time until symptoms are controlled or when the disease has partially or completely regressed.In addition, it should be noted that the clinician or treating physician knows when and how to interrupt, adjust and terminate the use of the arsenic trioxide composition as a medicine in conjunction with the response of each individual patient.

[0090] The effect of the arsenic-containing freeze-dried composition of the present invention on the development and progression of hematological malignancies can be observed by any method known to those skilled in the art, including, but not limited to, a) measuring changes in tumor size and morphology using imaging techniques, such as computed tomography (CT) scans or ultrasound images; and b) measuring changes in levels of biological markers of risk for hematological malignancies.

[0091] In certain embodiments, the toxicity and efficacy of the preventive and / or therapeutic protocols of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index, and can be expressed as the LD50 / ED50 ratio. Prophylactic and / or therapeutic agents that exhibit large therapeutic indexes are preferred. Prophylactic and / or therapeutic agents that exhibit side effects can be used, but care should be taken to design a delivery system that targets the agent to the site of affected tissue, so as to minimize potential damage to non-infected cells, thereby reducing side effects.

[0092] In other embodiments, data obtained from cell culture assays and animal studies can be used to formulate a range of doses of prophylactic and / or therapeutic agents for use in humans. The dose of such agents is preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. Dosages can vary within this range depending on the dosage form used and the route of administration utilized. For any agent used in the methods of the present invention, a therapeutically effective dose can be estimated initially from cell culture assays. Doses can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0093] The anti-cancer activity of the treatments used according to the present invention can also be determined by various experimental animal models for cancer research, such as mouse models or transgenic mice. Below are some assays provided by way of example and not limitation.

[0094] The lyophilized composition containing arsenic of the present invention is prepared as described in the following description and experimental section. Arsenic or one or more of its chemical forms is an active ingredient, and may contain pharma- ceutically acceptable carriers or additives, and / or other ingredients as appropriate, provided that these ingredients do not impair (e.g., reduce) the activity of the lyophilized composition containing arsenic. Other ingredients that may be incorporated into the lyophilized composition containing arsenic of the present invention include, but are not limited to, herbs (including traditional Chinese medicine preparations), herbal extracts, vitamins, amino acids, metal salts, metal chelates, colorants, flavor enhancers, preservatives, and the like.

[0095] Any dosage form may be used to provide an effective dose of oral composition to a subject. Dosage forms include tablets, capsules, dispersions, suspensions, liquids, etc. In one embodiment, the composition of the present invention suitable for oral administration may be present as separate units, such as capsules, blisters, cachets, or tablets, each containing a predetermined amount of activated or prepared yeast, as powder or granules, or as a solution or suspension in aqueous liquid, non-aqueous liquid, oil-in-water emulsion, or water-in-oil liquid emulsion. In a preferred embodiment, the oral composition is in the form of a lyophilized powder or dispersible solid. In general, the composition is produced by uniformly and intimately mixing the active ingredient with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired form. Such products may be used as medicines or dietary supplements depending on the dosage and situation of use.

[0096] The oral compositions of the invention may further comprise a binder (e.g., partially pregelatinized starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); a binder or excipient (e.g., lactose, pentosan, microcrystalline cellulose or calcium hydrogen phosphate); a lubricant (e.g., magnesium stearate, talc or silica); a disintegrant (e.g., potato starch or sodium starch glycolate); or a wetting agent (e.g., sodium lauryl sulfate). Tablets or capsules may be coated by methods well known in the art.

[0097] In certain embodiments, the lyophilized composition comprising arsenic comprises the equivalent of about 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24 or 25 mg of arsenic trioxide per mL.

[0098] Generally, because of the ease of administration, tablet and capsule represent the most advantageous oral dosage unit form, and in this case, the above-mentioned solid pharmaceutical carrier is used.In a preferred embodiment, the composition is a capsule.Capsule can be formulated by any commercially available method. In certain embodiments, the composition is a capsule containing a lyophilized composition comprising 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 24 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, or 50 mg of arsenic in powder form.

[0099] Further examples of anti-cancer agents that may be used in various embodiments of the present invention, including the pharmaceutical compositions and dosage forms and kits of the present invention, include, but are not limited to, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; amethanthrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busu Lufan;Cactinomycin;Calsterone;Caracemide;Carbetimer;Carboplatin;Carmustine;Carubicin hydrochloride;Carzelesin;Cedefingol;Chlorambucil;Cirolemycin;Cisplatin;Cladribine;Crisnatol mesylate;Cyclophosphamide;Cytarabine;Dacarbazine;Dactinomycin;Daunorubicin hydrochloride;Decitabine;Dexormaplatin;Desaguanine;Desaguanine mesylate;Diazicon;Docetaxel;Doxorubicin;Doxorubicin hydrochloride;Droloxifene;Droloxifene citrate;Dromostanolone propionate;Duazomycin;Edatrexate;Eflomithine hydrochloride hydrochloride);elsamitrucin;enloplatin;enpromate;epipropizine;epirubicin hydrochloride;erbulozole;esorubicin hydrochloride;estramustine;estramustine sodium phosphate;etanidazole;etoposide;etoposide phosphate;etoprine;fadrozole hydrochloride;fazarabine;fenretinide;floxuridine;fludarabine phosphate;fluorouracil;flurocitabine;foskidone;fostriecin sodium;gemcitabine;gemcitabine hydrochloride;hydroxyurea;idarubicin hydrochloride;ifosfamide;irmofosine;Interleukin II (including recombinant interleukin II or rIL2); interferon alpha-2a; interferon alpha-2b; interferon alpha-n1; interferon alpha-n3; interferon beta-Ia; interferon gamma-Ib; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitochromine ( mitocromin;mitodilin;mitomalcin;mitomycin;mitosper;mitotane;mitoxantrone hydrochloride;mycophenolic acid;nocodazole;nogalamycin;ormaplatin;oxisuran;paclitaxel;pegaspargase;periomycin;pentamustine;peplomycin sulfate;perfosfamide;pipobroman;piposulfan;piroxantrone hydrochloride ;Plicamycin;Promestane;Porfimer sodium;Porfiromycin;Prednimustine;Procarbazine hydrochloride;Puromycin;Puromycin hydrochloride;Pyrazofurin;Riboprin;Logretimide;Safingol;Safingol hydrochloride;Semustine;Simtrazene;Sparphosate sodium;Sparsomycin;Spirogermanium hydrochloride;Spiromustine;Spiroplatin;Streptonigrin;Streptozocin;Sulofenur;Tallysomycin;Tecogalanthrene Um;tegafur;teloxantrone hydrochloride;temoporfin;teniposide;teloxylone;testolactone;thiamiprine;thioguanine;thiotepa;tiazofurin;tirapazamine;toremifene citrate;trestolone acetate;triciribine phosphate;trimetrexate;trimetrexate glucuronate;triptorelin;tubrozole hydrochloride;uracil mustard;uredepa;vapreotide;verteporfin;vinblastine sulfate;Vincristine sulfate; Vindesine; Vindesine sulfate; Binepidine sulfate; Vinglycinate sulfate; Vinleurosine sulfate; Vinorelbine tartrate; Vinrosidine sulfate; Vinzolidine sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin hydrochloride. ; Other anti-cancer drugs include, but are not limited to, 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist Streptococcus G;antarelix;anti-dorsal morphogenetic protein-1;antiandrogen, prostate cancer;antiestrogens;antineoplastic drugs;antisense oligonucleotides;aphidicolin glycinate;apoptotic gene modulators;apoptotic regulators;apurinic acid;ara-CDP-DL-PTBA;arginine deaminase;asulacrine;atamestane;atrimutine;axinastatin 1;axinastatin 2;axinastatin 3;azasetron;azatoxin;azatidine Rosin;Baccatin III derivatives;Balanol;Batimastat;BCR / ABL antagonists;Benzochlorin;Benzoylstaurosporine;β-lactam derivatives;β-alethine;Betaclamycin B;Betulinic acid;bFGF inhibitors;Bicalutamide;Bisantrene;Bisaziridinylspermine;Bisnafide;Bistratene A;Bizelesin;Breflate;Bropirimine;Budotitanium;Buthionine sulfoximine;Calciporin Triol;calphostin C;camptothecin derivatives;canarypox IL-2;capecitabine;carboxamide-aminotriazole;carboxyamidotriazole;CaRestM3;CARN700;cartilage-derived inhibitor;calzelesin;casein kinase inhibitor (ICOS);castanospermine;cecropin B;cetrorelix;chlorins;chloroquinoxaline sulfonamides;cicaprost;cisporphyrins;cladribine;clomiphene analogs;clotrimazole;collismycin A;Collismycin B; Combretastatin A4; Combretastatin analog; Conagenin; Crambescidin 816; Crisnatol; Cryptophycin 8; Cryptophycin A derivative; Curacin A; Cyclopentanthraquinone; Cycloplatam; Cypemycin; Cytarabine ocfosfate; Cytolytic factor; Cytostatin; Dacliximab; Decitabine; Dehydrodydemnin drodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diazicon; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dihydrotaxol; dioxamycin; diphenylspiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine edrecolomab;eflomithine;elemene;emiteflu;epirubicin;epristeride;estramustine analogs;estrogen agonists;estrogen antagonists;etanidazole;etoposide phosphate;exemestane;fadrozole;fazarabine;fenretinide;filgrastim;finasteride;flavopiridol;flezelastine;fluasterone;fludarabine;fluorodaunorunicin hydrochloride;forfenimex;formestane;fostriecin ;Fotemustine;Gadolinium texaphyrin;Gallium nitrate;Galocitabine;Ganirelix;Gelatinase inhibitors;Gemcitabine;Glutathione inhibitors;Hepsulfam;Heregulin;Hexamethylene bisacetamide;Hypericin;Ibandronate;Idarubicin;Idoxifene;Idramantone;Ilmofosine;Ilomastat;Imidazoacridones;Imiquimod;Immunostimulatory peptides;Insulin-like growth factor-1 receptor inhibitors;Interferon agonists;Interferon;Interleukin;Iobenguane;Iododoxorubicin;Ipomeanol, 4-;Iropract;Irsogladine;Isobengazole;Isohomohalichondrin B;Itasetron;Jasplakinolide;Kahalalide F;Lamellarin-N triacetate;Lanreotide;Leinamycin;Lenograstim;Lentinan sulfate;Leptolstatin;Letrozole;Leukemia inhibitory factor;Leukocyte alpha interferon Feron; leuprolide + estrogen + progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogs; lipophilic disaccharide peptides; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lutotecan; lutetium texaphyrin; lysofylline; lytic peptides; maytansine; mannostatin A; marimastat; masoprocol; ma SPIN; Matrilysin inhibitors; Matrix metalloproteinase inhibitors; Menogaril; Merbarone; Meterelin; Methioninase; Metoclopramide; MIF inhibitors; Mifepristone; Miltefosine; Millimostim; Mismatched double-stranded RNA; Mitoguazone; Mitolactol; Mitomycin analogs; Metnafide; Mitotoxin fibroblast growth factor-saponin; Mitoxantrone; Mofalotene; Molgramostim; Monoclonal antibodies, human chorionic gonadotropin; Monophosphoryl lipid A+ Myobacterium cells wall sk;multidrug resistance gene inhibitors;multiple tumor suppressor 1-based therapy;mopidamol;mustard anticancer drugs;mycaperoxide B;actinomycete cell wall extract;myriaporone;N-acetyldinaline;N-substituted benzamides;nafarelin;nagrestip;naloxone + pentazocine;napavin;naphterpine;nartograstim;nedaplatin;nemorubicin;neridronic acid;neutral endopeptidase;nilutamide;Nisamycin;Nitric oxide modulators;Nitric oxide antioxidants;Nitrulline;06-benzylguanine;Octreotide;Oxenone;Oligonucleotides;Onapristone;Ondansetron;Oracin;Oral cytokine inducers;Ormaplatin;Osalaron;Oxaliplatin;Oxaunomycin;Paclitaxel;Paclitaxel analogs;Paclitaxel derivatives;Palauamine e);palmitoyl rhizoxin;pamidronic acid;panaxytriol;panomyphen;parabactin;pazeliptin;pegaspargase;perdecin;sodium pentosan polysulfate;pentostatin;pentrozole;perflubron;perphosphamide;perillyl alcohol;phenazinomycin;phenyl acetate;phosphatase inhibitors;picibanil;pilocarpine hydrochloride;pirarubicin;piritrexim;placetin A;placetin B;plasminogen activator inhibitors;platinum complexes;platinum compounds; Platinum-triamine complexes;Porfimer sodium;Porfiromycin;Prednisone;Propyl bis-acridone;Prostaglandin J2;Proteasome inhibitors;Protein A-based immunomodulatory components;Protein kinase C inhibitors;Protein kinase C inhibitors, microalgae;Protein tyrosine phosphatase inhibitors;Purine nucleoside phosphorylase inhibitors;Purpurin;Pyrazoloacridine;Pyridoxyl oxidized hemoglobin polyoxyethylene conjugates;raf antagonists;Raltitrexed;Ramosetron;Rasfa Famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitors; demethylated reterliptin; rhenium Re186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxil; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi1 mimic; semustine; senescence derived inhibitor 1; sense oligonucleotides;Signal transduction inhibitors;Signal transduction modulators;Single-chain antigen-binding proteins;Sizofiran;Sobuzoxane;Sodium borocaptate;Phenylsodium acetate;Sorberol;Somatomedin-binding proteins;Sonermin;Sparfosic acid;Spicamycin D;Spiromustine;Splenopentin;Spongistatin 1;Squalamine;Stem cell inhibitors;Stem cell division inhibitors;Stipiamide;Stromelysin inhibitors;Sulfinosine;Superactive vasoactive intestinal peptide antagonists;Slajista;Suramin;Swainsonine;Synthetic glycosaminoglycans;Talimustine;Tamoxifen methiodide;Tauromustine;Tazarotene;Tecogalan sodium;Tegafur;Tellurapyrylium;Telomerase inhibitors;Temoporfin;Temozolomide;Teniposide;Tetrachlorodecaoxide;Tetrazomine;Tali thaliblastine;thiocoraline;thrombopoietin;mimetic thrombopoietin;thymalfasin;thymopoietin receptor agonist;thymotrinan;thyrotropin;tin ethyl etiopurpurin;tirapazamine;titanocene dichloride;topsentin;toremifene;totipotent stem cell factor;translation inhibitors;tretinoin;triacetyluridine;triciribine;trimetrexate;triptorelin;tropisetron;turosteride ;tyrosine kinase inhibitors;tyrophostins;UBC inhibitors;ubenimex;urogenital sinus-derived growth inhibitory factor;urokinase receptor antagonists;vapreotide;variolin B;vector systems, red blood cell gene therapy;veraresol;veramine;verdins;verteporfin;vinorelbine;vinxartin;vitaxin;vorozole;zanoterone;zeniplatin;zilascorub;andzinostatin stimalamer. Preferred additional anticancer agents are 5-fluorouracil and leucovorin. These two agents are particularly useful when used in methods employing thalidomide and topoisomerase inhibitors.;

[0100] formulation In a preferred embodiment, the present invention provides a method for producing a freeze-dried composition comprising arsenic, alternatively referred to as freeze-dried arsenic trioxide (As2O3), comprising: a. solubilizing As2O3 powder in water in a vessel, in the following order: i. adding an alkalizing agent to the vessel to achieve a pH of about 12 or greater; ii. adding an acid to the vessel to adjust the pH to about 7 to about 8; iii. adding a surfactant to the vessel; and iv. adding water to the vessel to produce an As2O3 solution. a solubilizing step comprising: b. freeze-drying the As2O3 solution The present invention relates to a method comprising the steps of:

[0101] In one embodiment of the above method, the alkalizing agent comprises sodium hydroxide (NaOH) or sodium carbonate (Na2CO3). In another embodiment, the amount of the alkalizing agent added is about 10% to about 100% of the amount of the As2O3 powder. In other words, the amount of the alkalizing agent added is about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 121, 122 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100%. In another embodiment, the amount of alkalizing agent added is any number within the range defined by and including any two numbers above.

[0102] In yet another embodiment, the acid comprises hydrochloric acid (HCl). In one embodiment, the HCl is about 6M HCl. In one embodiment, acid is added to the vessel to adjust the pH to about 7.2. In one embodiment, water is added to the vessel after steps a)i), a)ii), a)iii), and / or a)iv).

[0103] In one embodiment of the invention, the surfactant comprises sodium lauryl sulfate, Tween 80, beta cyclodextrin, poloxamer, and tocopheryl polyethylene glycol succinate (TPGS). In one embodiment of the invention, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but not to exceed about 50% of the As2O3 concentration.

[0104] In one embodiment of the present invention, the freeze-drying step comprises freezing the As2O3 solution to produce a frozen As2O3 product, and drying the frozen As2O3 product to produce the freeze-dried As2O3 or arsenic-containing freeze-dried composition.In another embodiment, the freezing step comprises freezing the As2O3 solution at about -40°C.In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours.In one embodiment, the drying step comprises applying heat and vacuum to the As2O3 solid. For example, drying steps include heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product at about 10°C and about 500 mTorr for about 60 minutes; heating the As2O3 product at about 25°C and about 500 mTorr for about 180 minutes.

[0105] In another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr for about 60 minutes, and holding at about 25° C. and about 500 mTorr for about 180 minutes.

[0106] In one embodiment, the drying step further comprises heating the As2O3 product at about 25° C. and about 500 mTorr for about 120 minutes after said heating of the As2O3 product at about 25° C. and about 500 mTorr for about 180 minutes.

[0107] The present invention also provides a method for producing an oral formulation comprising LCCA, comprising: c. Solubilizing As2O3 powder in water in a vessel, in the following order: i. adding an alkalizing agent to the vessel to achieve a pH of about 12 or greater; ii. adding an acid to the vessel to adjust the pH to about 7 to about 8; iii. adding a surfactant to the vessel; and iv. adding water to the vessel to produce an As2O3 solution. a solubilizing step comprising: d. freeze-drying the As2O3 solution to produce lyopremix; e. sieving the lyopremix to produce LCCA powder; f. adding a filler to the LCCA powder; g. adding one or more lubricants to the LCCA powder to form the oral dosage form containing LCCA. The present invention relates to a method comprising the steps of:

[0108] In one embodiment of the above method, the alkalizing agent comprises sodium hydroxide (NaOH) or sodium carbonate (Na2CO3). In another embodiment, the amount of the alkalizing agent added is about 10% to about 100% of the amount of As2O3 powder. In yet another embodiment, the acid comprises hydrochloric acid (HCl). In one embodiment, the HCl is about 6 M HCl. In one embodiment, acid is added to the vessel to adjust the pH to about 7.2. In one embodiment, water is added to the vessel after steps c)i), c)ii), c)iii), and / or c)iv).

[0109] In one embodiment of the invention, the surfactant comprises sodium lauryl sulfate, Tween 80, beta cyclodextrin, poloxamer, and tocopheryl polyethylene glycol succinate (TPGS). In one embodiment of the invention, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but not to exceed about 50% of the As2O3 concentration.

[0110] In one embodiment of the present invention, the freeze-drying step comprises freezing the As2O3 solution to produce a frozen As2O3 product, and drying the frozen As2O3 product to produce the freeze-dried As2O3.In another embodiment, the freezing step comprises freezing the As2O3 solution at about -40°C.In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours.In one embodiment, the drying step comprises applying heat and vacuum to the As2O3 product solid. For example, drying steps include heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product at about 10°C and about 500 mTorr for about 60 minutes; heating the As2O3 product at about 25°C and about 500 mTorr for about 180 minutes.

[0111] In another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr for about 60 minutes, and holding at about 25° C. and about 500 mTorr for about 180 minutes.

[0112] In one embodiment, the drying step further comprises heating the As2O3 product at about 25° C. and about 500 mTorr for about 120 minutes after said heating of the As2O3 product at about 25° C. and about 500 mTorr for about 180 minutes.

[0113] In one embodiment of the above invention, the filler comprises mannitol. In another embodiment, the one or more lubricants comprise talc and / or magnesium stearate.

[0114] In a further step, the invention comprises filling a capsule with the oral formulation.

[0115] The present invention also relates to a pharmaceutical composition in solid dosage form suitable for oral administration, comprising lyophilized arsenic trioxide, also known as lyophilized composition containing arsenic, at least one filler and at least one lubricant.

[0116] In one embodiment, the pharmaceutical composition comprises: h. solubilizing As2O3 powder in water in a vessel in the following order: v. adding an alkalizing agent to the vessel to achieve a pH of about 12 or greater; vi. adding an acid to the vessel to adjust the pH to about 7 to about 8; vii. adding a surfactant to the vessel; and viii. adding water to the vessel to produce an As2O3 solution. a solubilizing step comprising: i. lyophilizing the As2O3 solution to produce a lyopremix; j. sieving the lyopremix to produce an LCCA powder; k. adding a filler to the LCCA powder; l. adding one or more lubricants to the LCCA powder to form an oral dosage form of the As2O3. The method is produced by a method comprising:

[0117] In one embodiment, Lyopremix or LCCA has a mean particle size distribution D(90) of about 2 μm to 10 μm. In other words, the particle size distribution D(90) of Lyopremix measured in μm is 2, 3, 4, 5, 6, 7, 8, 9 and 10 μm, or a number within a range defined by any two numbers thereof.

[0118] In one embodiment, the lyopremix or LCCA has an average particle size distribution D(10) of about 0.2 μm to 3 μm. In other words, the particle size distribution D(10) of the lyopremix measured in μm is 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.9, 1.0, 1.1, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 μm, or any number within a range defined by two of those numbers.

[0119] In one embodiment, the lyopremix or LCCA has a mean particle size distribution D(50) of about 0.5 μm to 4 μm. In other words, the particle size distribution D(50) of the lyopremix measured in μm is 0.5, 0.6, 0.7, 0.9, 1.0, 1.1, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 4.0 μm, or any number within a range defined by two of those numbers.

[0120] In one embodiment, the Lyopremix or LCCA has a particle size D(90) that is 10 to 50 times smaller than the API. In other words, the D(90) of the Lyopremix is ​​10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 times smaller than the D(90) of the API.

[0121] In one embodiment, the lyopremix or LCCA surface area is about 0.5 m 2 / g ~ approx. 5 m 2 In other words, the surface area is in the range of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 and 5.0 m 2 / g, or a number within a range defined by any two numbers herein.

[0122] In one embodiment, the surface area of ​​the lyopremix or LCCA is 2 to 80 times greater than the surface area of ​​the API powder as measured by the BET method. In other words, the BET surface area of ​​the lyopremix is ​​2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80 times.

[0123] In one embodiment, Lyopremix or LCCA dissolves in cold water. In another embodiment, Lyopremix or LCCA dissolves in cold water (room temperature) about 2 times to about 30 times more than API powder. In other words, Lyopremix or LCCA dissolves in cold water (room temperature) about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 times more than API powder. In one embodiment, Lyopremix or LCCA dissolves in alcohol. In another embodiment, Lyopremix or LCCA dissolves in alcohol about 2 times to 30 times more than API powder. In other words, the Liopremix or LCCA is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 times more soluble in alcohol than the API powder.

[0124] From the scanning electron micrographs, it is observed that Lyopremix or LCCA particles have porous properties that may contribute to the higher solubility, higher surface area and smaller average particle size of Lyopremix.

[0125] In one embodiment of the pharmaceutical composition, the alkalizing agent comprises sodium hydroxide (NaOH) or sodium carbonate (Na2CO3). In another embodiment, the amount of the alkalizing agent added is about 10% to about 100% of the amount of As2O3 powder. In yet another embodiment, the acid comprises hydrochloric acid (HCl). In one embodiment, the HCl is about 6M HCl. In one embodiment, acid is added to the vessel to adjust the pH to about 7.2. In one embodiment, water is added to the vessel after steps h)i), h)ii), h)iii), and / or h)iv).

[0126] In one embodiment of the invention, the surfactant comprises sodium lauryl sulfate, Tween 80, beta cyclodextrin, poloxamer, and tocopheryl polyethylene glycol succinate (TPGS). In one embodiment of the invention, the surfactant is added to about 0.5% v / v to about 4.0% v / v, but not to exceed about 50% of the As2O3 concentration.

[0127] In one embodiment of the present invention, the freeze-drying step comprises freezing the As2O3 solution to produce a frozen As2O3 product, and drying the frozen As2O3 product to produce the freeze-dried As2O3.In another embodiment, the freezing step comprises freezing the As2O3 solution at about -40°C.In another embodiment, the As2O3 solution is frozen at about -40°C for at least about 6 hours.In one embodiment, the drying step comprises applying heat and vacuum to the As2O3 solid. For example, drying steps include heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product at -20°C and 500 mTorr for about 120 minutes; heating the As2O3 product at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product at about 10°C and about 500 mTorr for about 60 minutes; heating the As2O3 product at about 25°C and about 500 mTorr for about 180 minutes. In another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr for about 60 minutes, and holding at about 25° C. and about 500 mTorr for about 180 minutes.

[0128] In one embodiment, the drying step further comprises heating the As2O3 product at about 25° C. and about 500 mTorr for about 120 minutes after said heating of the As2O3 product at about 25° C. and about 500 mTorr for about 180 minutes.

[0129] In one embodiment of the above invention, the filler comprises mannitol. In another embodiment, the one or more lubricants comprise talc and / or magnesium stearate.

[0130] In one embodiment, the pharmaceutical composition comprises lyophilized arsenic trioxide, mannitol, talc and magnesium stearate.In another embodiment, the pharmaceutical composition is a controlled release solid pharmaceutical composition.In another embodiment, the pharmaceutical composition is encapsulated.

[0131] In one embodiment, the capsule contains about 1 mg, 5 mg, 10 mg and 20 mg of the above pharmaceutical composition.

[0132] The present invention also relates to a kit comprising the above pharmaceutical composition and instructions for its use.

[0133] In one embodiment, the present invention relates to a method for treating hematopoietic tumors in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition described above.

[0134] By way of example, the hematopoietic tumor is acute myeloid leukemia, acute nonlymphocytic leukemia, myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, myelodysplastic syndrome, acute promyelocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, giant cell myeloma, asymptomatic myeloma, localized myeloma, multiple myeloma, plasma cell myeloma, sclerosing myeloma, solitary myeloma, smoldering multiple myeloma, nonsecretory myeloma, osteosclerosing myeloma, plasma cell leukemia, solitary plasmacytoma or extramedullary plasmacytoma.

[0135] In one embodiment, the hematopoietic malignancy is acute promyelocytic leukemia (APL). In a further embodiment of the present invention, the APL is newly diagnosed APL, or relapsed or refractory APL.

[0136] In one embodiment, the pharmaceutical composition is administered daily. In another embodiment, the pharmaceutical composition is administered daily for 52 weeks / year. In yet another embodiment, the pharmaceutical composition is administered in a single dose ranging from about 1 mg to about 50 mg. In another embodiment, the pharmaceutical composition is administered in a single dose ranging from about 0.1 mg / kg body weight to about 0.3 mg / kg body weight.

[0137] In one embodiment of the present invention, the patient has been previously or is currently being treated with chemotherapy and / or radiation.In another embodiment, the treatment method further comprises administering one or more chemotherapeutic agents to the patient.The chemotherapeutic agents are administered before, after or simultaneously with the pharmaceutical composition.The present invention also relates to a composition comprising LCCA or lyophilized arsenic trioxide, at least one filler and at least one lubricant.In one embodiment, the lyophilized arsenic trioxide is: m. solubilizing As2O3 powder in water in a vessel in the following order: ix. adding an alkalizing agent to the vessel to achieve a pH of about 12 or greater; x. adding an acid to the vessel to adjust the pH to about 7 to about 8; xi. adding a surfactant to the vessel; and xii. adding water to the vessel to produce an As2O3 solution. a solubilizing step comprising: freeze-drying the As2O3 solution In one embodiment, the alkalizing agent comprises sodium hydroxide (NaOH) or sodium carbonate (Na2CO3). In another embodiment of the invention, the amount of the alkalizing agent added is about 10% to about 100% of the amount of As2O3. In one embodiment, the acid comprises hydrochloric acid (HCl), preferably about 6M HCl. In another embodiment, acid is added to the vessel to adjust the pH to about 7.2. In another embodiment, water is added to the vessel after steps m)i), m)ii), m)iii), and / or m)iv).

[0138] In one embodiment, the surfactants include sodium lauryl sulfate, Tween 80, beta cyclodextrin, poloxamer, and tocopheryl polyethylene glycol succinate (TPGS). The surfactants are added at about 0.5% v / v to about 4.0% v / v, but do not exceed about 50% of the As2O3 concentration.

[0139] Freeze drying Freezing process In one embodiment, the freeze-drying step comprises freezing the As2O3 solution to produce a frozen As2O3 product, and drying the frozen As2O3 product to produce freeze-dried As2O3. In one embodiment, the lyophilization step comprises freezing the As2O3 solution to at least one temperature from -50, -49, -48, -47, -46, -45, -44, -43, -42, -41, -40, -39, -38, -37, -36, -35, -34, -33, -32, -31, -30, 29, -28, -27, -26, -25, -24, -23, -22, -21, -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -09, -08, -07, -06, -05, -04, -03, -02, -01, and 0 °C. In another embodiment, the freezing temperature is selected from the range defined by any two numbers above and inclusive. In another embodiment, the freezing step comprises freezing the As2O3 solution at about -40°C for at least 6 hours. The freezing step may have several freezing sub-steps with gradually decreasing temperature. The freezing steps and / or freezing sub-steps may each be from about 5 minutes to about 500 minutes, i.e., may include all numbers within the range, such as 6, 7, 8, 9, ..., 497, 498, 499 and 500 minutes.

[0140] Sublimation process In one embodiment, sublimation (primary drying) or secondary drying is carried out at a temperature ranging from -50° C. to 35° C. In other words, sublimation can be achieved at the following temperatures: -50, -49, -48, -47, -46, -45, -44, -43, -42, -41, -40, -39, -38, -37, -36, -35, -34, -33, -32, -31, -30, -29, -28, -27, -26, -25, -24, -23, -22, -21, -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35. In one embodiment, the sublimation temperature can be any temperature within the range defined by and including any two numbers above. In one embodiment, more than one sublimation temperature is used.

[0141] Secondary drying may be carried out at higher temperatures, for example at temperatures between 35°C and 75°C.

[0142] Primary or secondary drying at different temperatures can be for times between 5 minutes and 500 minutes, i.e., including all numbers within the range, e.g., 6, 7, 8, 9, ..., 497, 498, 499 and 500 minutes. Secondary drying can be for longer times, e.g., up to 1000 minutes.

[0143] Vacuum application The vacuum can be applied simultaneously with or independently of drying. The vacuum can be applied during drying from one temperature to a second (higher) temperature or during a hold at one temperature. The vacuum application can be alternated with the drying. The vacuum applied during the drying step can be in the range of about 300 mTorr to about 1000 mTorr. In one embodiment, the vacuum is applied at 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 50, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990 and 1000 mTorr, inclusive, or a number within a range defined by any two numbers herein.

[0144] Drying step includes applying heat and vacuum to the As2O3 product.In one embodiment, drying step includes heating the As2O3 product at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product at about 25°C and about 500 mTorr for about 180 minutes. In another embodiment, the drying step comprises heating the As2O3 product to about -30°C and about 800 mTorr for about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; heating the As2O3 product to about -20°C and about 500 mTorr for about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about -5°C and about 500 mTorr for about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; heating the As2O3 product to about 10°C and about 500 mTorr for about 120 minutes and holding at about 10°C and about 500 mTorr for about 60 minutes; and heating the As2O3 product to about 25°C and about 500 mTorr for about 60 minutes. The method includes heating to about 25° C. and about 500 mTorr for about 60 minutes, and holding at about 25° C. and about 500 mTorr for about 180 minutes.

[0145] In yet another embodiment, the drying step further comprises heating the As2O3 product at about 25° C. and about 500 mTorr for about 120 minutes after said heating of the As2O3 product at about 25° C. and about 500 mTorr for about 180 minutes.

[0146] In one embodiment of the composition, the filler comprises mannitol and the one or more lubricants comprise talc and / or magnesium stearate.

[0147] The present invention also relates to the above composition comprising lyophilized arsenic trioxide, mannitol, talc and magnesium stearate.

[0148] In one embodiment, for the compositions and methods described herein, the LCCA is used in a therapeutically effective amount. EXAMPLES

[0149] experiment The control formulation was injectable As2O3, available in injection form with a strength of 10 mg / 10 mL. The test formulation development was provided in solid form for oral use. Test formulation development was initiated as 1 mg, 5 mg, 10 mg and 20 mg capsules. The freeze-drying technique was selected to modify the physical and / or chemical properties of arsenic trioxide, including reducing particle size, increasing surface area, and developing other morphological properties that may be useful for its solubility, dissolution and / or bioavailability of pharmaceutical formulations. Appropriate excipients were selected and concentrations were optimized to achieve a smooth freeze-drying process that resulted in improved solubility of arsenic trioxide. Laboratory scale stability data at 40°C / 75% RH for 15 days was found to be satisfactory.

[0150] Control formulation--injectable form--arsenic trioxide According to the package insert for injectable arsenic trioxide, arsenic trioxide induces morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also induces damage or degradation of the fusion protein PML / RAR-α.

[0151] Arsenic trioxide in solution hydrolyzes to the pharmacologically active species arsenous acid (AsIII). Monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (Asv), the product of AsIII oxidation.

[0152] The pharmacokinetics of arsenic species ([AsIII], [Asv], [MMAV], [DMAV]) were measured in six APL patients after administration of 0.15 mg / kg once daily for 5 days per week. Over a total single dose range of 7 to 32 mg (administered as 0.15 mg / kg), systemic exposure (AUC) appeared to be linear. Peak plasma concentrations of arsenite (AsIII), the main active arsenic species, were reached at the end of the infusion (2 h). AsIII plasma concentrations declined in a biphasic manner with a mean elimination half-life of 10 to 14 h, characterized by an initial rapid distribution phase followed by a slower elimination phase. Daily exposure to Asm (mean AUC 0-24 ) was 194 ng-hr / mL (n=5) on day 1 of cycle 1 and 332 ng-hr / mL (n=6) on day 25 of cycle 1, representing approximately a 2-fold accumulation.

[0153] The main pentavalent metabolites, MMAV and DMAV, are slow to appear in plasma (approximately 10-24 hours after the first dose of arsenic trioxide) but accumulate more with multiple doses than AsIII due to their longer half-lives. The mean estimated terminal elimination half-lives of the metabolites MMAV and DMAV are 32 and 72 hours, respectively. Approximate accumulation ranged from 1.4- to 8-fold after multiple doses compared to single dose administration. Asv is only present in plasma at relatively low levels.

[0154] distribution The volume of distribution (Vss) of AsIII was large (mean 562 L, N = 10), which is due to the III This indicates that Vss is widely distributed throughout body tissues. Vss is also weight dependent, increasing as body weight increases.

[0155] metabolism As III Most of the cytotoxicity of the metabolite monomethylarsonic acid (MMA) is distributed to tissues, where it is secreted by the cytotoxic metabolite monomethylarsonic acid (MMA). V ) and dimethylarsinic acid (DMA VArsenic trioxide is methylated mainly in the liver by methyltransferase. III As v This involves the oxidation of As to As, which can occur in many tissues by enzymatic or nonenzymatic processes. v is present in plasma only at relatively low levels following administration of arsenic trioxide.

[0156] excretion Approximately 15% of the administered arsenic trioxide injection dose was unchanged. III It is excreted in the urine as As. III The methylated metabolites of As (MMAV, DMAV) are mainly excreted in the urine. III The total clearance is 49 L / h and the renal clearance is 9 L / h. Clearance is independent of body weight or the dose administered, which ranges from 7 to 32 mg.

[0157] As 2 O 3 development The active pharmaceutical ingredient arsenic trioxide for these experiments was purchased from Sigma-Aldrich as a white powder with a molecular weight of 197.8 g / mole, with the general chemical formula of As2O3.

[0158] For comparative examples, an injectable form of arsenic trioxide was purchased as Arsenox® (manufactured by Naprod Life sciences private limited for Intas pharma, India). Arsenic trioxide injection is indicated for induction of remission and remission in patients with acute promyelocytic leukemia (APL). It is provided in injection vial form with a strength of 10 mg / 10 mL (1 mg / mL) ampule.

[0159] The control formulation was available in an injectable form and the test formulation development was in oral solid form, so the subject formulation was not subject to stability constraints.

[0160] No drug additive studies were performed. Solubility studies were performed as part of the development with various surfactants and solvents.

[0161] Formulation development Arsenic trioxide, available in injectable form, and a development grade powder for oral administration were tested. Powder form of As2O3 was lyophilized to modify the physical and / or chemical properties of arsenic trioxide, including reducing particle size, increasing surface area, and generating other morphological properties that may be useful for its solubility, arsenic dissolution, and / or bioavailability.

[0162] Lyophilization, also known as freeze drying, involves removing purified water from liquid, paste, or solid forms using freezing and vacuum evaporation cycles without melting the ice. Water (ice) in the solid state exposed to extremely low pressure, e.g., vacuum, sublimes or proceeds directly from the solid to a gaseous state. The purified water vapor (or other solvent) remains trapped by freezing in a condenser or cold trap. This technique maintains the volume, appearance, and properties of the product being processed.

[0163] Generally, a freeze-drying cycle involves the following steps: 1. Freezing: The product is frozen. This provides the necessary conditions for low temperature drying. 2. Vacuum: After freezing, the product is placed under a vacuum or reduced pressure. This allows the freezing solvent in the product to evaporate without passing through a liquid phase, a process known as sublimation. 3. Heating: Heat is applied to the frozen product to accelerate sublimation. 4. Condensation: Cryogenic condensation removes the evaporated solvent from the vacuum chamber by converting it back to a solid. This completes the separation process.

[0164] The first step in the freeze-drying process is to freeze the product, solidifying all of its purified water molecules. Once frozen, the product is placed in a vacuum and slowly heated without melting the product. This process, called sublimation, converts ice directly to purified water vapor without first passing through a liquid state. The purified water vapor released by the product during the sublimation step condenses as ice on a collection trap, known as a condenser, within the vacuum chamber of the freeze dryer.

[0165] Freeze-drying has many advantages over other drying and preservation techniques. For example, freeze-drying maintains the quality of food / biochemical and chemical reagents because temperatures below the freezing point are maintained during the sublimation process. Freeze-drying is particularly important when processing lactic acid bacteria because these products are easily affected by heat. Freeze-dried food / biochemical and chemical reagents can usually be stored without refrigeration, which results in a significant reduction in storage and transportation costs. Freeze-drying significantly reduces weight, which makes the product easier to transport. For example, many foods contain as much as 90% purified water. These foods are 10 times lighter after freeze-drying. Many freeze-dried products can be easily rehydrated because they are porous. Freeze-drying does not significantly reduce volume; therefore, purified water easily regains its place in the molecular structure of the food / biochemical and chemical reagents.

[0166] Based on the literature and manufacturing process, various solubility enhancers such as sodium lauryl sulfate, Tween 80®, poloxamer, and pH adjusters to enhance solubility such as sodium hydroxide, sodium carbonate, sodium alginate, and hydrochloric acid were selected for initial development. The dissolution medium used for the initial development activities was 0.1 N HCl, 900 ml, paddle (mixed) at 100 rpm. A control formulation was available in one strength (10 mg / 10 mL) and test formulations were initiated in various strengths for oral administration with dose weight proportionality. Since the control formulation was available in 10 mg strength, formulation development was initiated with the 10 mg strength.

[0167] Experiment number L040 / 1 / 001 The objective of this experiment was to conduct a solubility study on arsenic trioxide using sodium hydroxide as a pH adjuster, surfactants, namely sodium lauryl sulfate and Tween 80®, and various solvents, such as isopropyl alcohol and ethanol.

[0168] In the first step, 4 g of arsenic trioxide was added to 600 mL of purified water in a vessel under stirring conditions. Then, about 35 mL of 3M NaOH (12 g of NaOH dissolved in 100 mL of purified water) was added dropwise under magnetic stirring at 1000 rpm for 15-30 minutes until a clear solution was formed. To this solution, 1 L of purified water was added. The pH was measured to be 12.7 units. The pH was adjusted to a target of 7-8 units with about 16.5 mL of 6M HCl (105.6 mL added to 200 mL of purified water). A pH of about 7.2 was observed. The solution was made up to 2 L with the addition of purified water. The pH remained unchanged at 7.3. [Table 1]

[0169] Experiment number L040 / 1 / 001B The purpose of this experiment was to carry out a solubility study on arsenic trioxide with sodium lauryl sulfate. In the first step, 50 g of purified water was taken in a glass beaker, to which 0.5 g of sodium lauryl sulfate was added under stirring until a clear solution was formed. Then, 5 g of As2O3 was added to the solution under stirring. Even after 30 minutes of stirring, As2O3 did not dissolve in the solution. In the next step, 30 g of purified water was added to determine if As2O3 would solubilize. No solubility was observed. After further addition of 2 g of sodium lauryl sulfate, no solubility was observed after 30 minutes of stirring. Two batches were produced: L040 / 1 / 001B1 and L040 / 1 / 001B2. The data are reported in Table 2 below. [Table 2]

[0170] Experiment number L040 / 1 / 001D The purpose of this experiment was to perform solubility enhancement for arsenic trioxide with cyclodextrin (kleptose). In the first step, 50 g of purified water was taken in a glass beaker and 0.5 g of cyclodextrin was added thereto under stirring until a clear solution was formed. 5 g of As2O3 drug was added to the above solution. Even after stirring for 30 minutes, As2O3 did not dissolve in the solution. An additional 30 g of purified water was added to the solution. As2O3 drug did not dissolve. After an additional addition of 2 g of cyclodextrin, As2O3 drug did not dissolve after stirring for 30 minutes. Table 3 summarizes the data from this experiment. [Table 3]

[0171] Experiment number L040 / 1 / 001E The purpose of this experiment was to perform solubility enhancement for arsenic trioxide with Tween 80®. In the first step, 50 g of purified water was taken in a glass beaker, to which 0.5 g of Tween 80® was added under stirring until a clear solution was formed. 5 g of As2O3 drug was added to this solution under stirring. Even after stirring for 30 minutes, As2O3 remained insoluble. An additional 30 g of purified water was added to this solution, but As2O3 remained insoluble. Even after an additional 2 g of Tween 80® was added to the solution, As2O3 did not dissolve even after stirring for 30 minutes. [Table 4]

[0172] Experiment number L040 / 1 / 001F The purpose of these experiments was to use various solvents for the solubility study of As2O3.

[0173] Isopropyl alcohol In a beaker, 1.5 g of As2O3 drug was added to 50 mL of isopropyl alcohol. The As2O3 did not dissolve even after stirring for 30 minutes. The drug did not dissolve even after adding an additional 30 mL of isopropyl alcohol and stirring for 30 minutes.

[0174] ethanol In a beaker, 1.5 g of As2O3 drug was added to 50 mL of ethanol. The drug did not dissolve after stirring for 30 minutes. The drug did not dissolve even after adding an additional 30 mL of ethanol and stirring for 30 minutes. Thus, from the above series of experiments, it was observed that only the L040 / 1 / 001A composition formed a clear solution.

[0175] Experiment number L040 / 1 / 002 The objectives of this experiment were to evaluate the exact amount of sodium hydroxide required to dissolve arsenic trioxide and to evaluate the effect of pH on the solubility of arsenic trioxide with various additives.

[0176] Experiment No. L040 / 1 / 002A - Amount of NaOH required to solubilize arsenic trioxide In a glass beaker, 30 mL of purified water was added and the pH was measured to be 6.7-7.0 units. To this solution, 200 mg As2O3 drug was added with stirring. The pH was observed to be about 5.6. As2O3 particles were observed floating in the solution. To this solution, 1N NaOH solution (4 g sodium hydroxide pellets dissolved in 100 mL of purified water) was added in a dropwise manner. The drug remained insoluble even after adding 0.6 mL of 1N NaOH and stirring for 10 minutes. The pH was measured to be about 9.21. An additional amount of 1.4 mL of 1N NaOH was added with stirring. The drug was still insoluble, pH 12.21. Subsequently, 1.6 mL of NaOH was added and stirred, and the drug was observed to dissolve at pH 12.37. An extra 200 mg of As2O3 drug was added to this solution, but it did not appear to dissolve in the solution (pH was 12.27). The addition of 2 mL of 1N NaOH was performed with stirring and the drug was found to dissolve at pH 12.33. When an additional 600 mg of drug was added to the solution, the drug was insoluble at pH 12.27. However, when 1N NaOH was added slowly (6.9 mL), the drug was found to dissolve at pH 12.39. Thus, 5 mg of sodium hydroxide was required to dissolve 10 mg of arsenic trioxide by maintaining a constant volume of 30 ml of purified water. [Table 5]

[0177] Experiment number L040 / 1 / 002B The purpose of this experiment was to evaluate the pH-dependent solubility (pH ~ 4) of arsenic trioxide with L-arginine. In a beaker, 200 mg of L-arginine was dissolved in 100 mL of purified water under continuous stirring (2 mg / mL solution). From this solution, 50 mL was used to dissolve 50 mg of the As2O3 drug. However, no dissolution was observed; the pH was 4.94. [Table 6]

[0178] Experiment number L040 / 1 / 002D The purpose of this experiment was to evaluate the pH-dependent solubility of arsenic trioxide with sodium bicarbonate (pH ~ 8). In a beaker, 200 mg of sodium bicarbonate was dissolved in 100 mL of purified water (2 mg / mL solution). From this solution, 50 mL was taken (pH 8.2) and 50 mg of As2O3 drug was added to it. No solubility was observed (pH 8.0). [Table 7]

[0179] Experiment number L040 / 1 / 002E The purpose of this experiment was to evaluate the pH-dependent solubility of arsenic trioxide with L-arginine base (pH ~ 12). In a beaker, 200 mg of L-arginine base was dissolved in 100 mL of purified water under continuous stirring (2 mg / mL solution). From this solution, 50 mL was used to dissolve 50 mg of the As2O3 drug (pH 10.90). However, no dissolution was observed; the pH was 10.53. [Table 8]

[0180] Experiment number L040 / 1 / 002F The purpose of this experiment was to evaluate the pH-dependent solubility of arsenic trioxide with sodium carbonate (pH ~ 12). In a beaker, 50 mg of sodium carbonate was added to 50 mL of purified water (1 mg / mL solution). To this solution, 50 mg of As2O3 drug was added to it under stirring at pH 11.25. No solubility of the drug was observed. However, when the concentration of sodium carbonate was gradually increased to 50 mg sodium carbonate / mL, arsenic trioxide was found to dissolve in solution at pH 11.46. [Table 9]

[0181] Thus, overall, the drug was insoluble over the entire pH range of 4 to 12 when using arginine, arginine base, or sodium bicarbonate, but was found to be soluble with higher concentrations of sodium carbonate (500 mg of sodium carbonate was required to dissolve 10 mg of arsenic trioxide).

[0182] Experiment number L040 / 1 / 002G The purpose of this experiment was to repeat the experiment of L040 / 1 / 002A, but using bulking agents such as lactose monohydrate and mannitol for subsequent freeze-drying. In a first step, 10 g of arsenic trioxide drug was added to 300 mL of purified water under stirring, followed by 125 mL of 1N NaOH under stirring. The drug was found to be soluble. The solution was divided into two equal parts:

[0183] L040 / 1 / 002G1: In the first portion, lactose monohydrate (3.5 g) was added under stirring and the solution was set aside for physical observation and subsequent freeze-drying (pH 12.34). After about 24 hours at room temperature the clear solution turned brown and after 36 hours the color intensity increased and turned dark brown so freeze-drying was not performed.

[0184] L040 / 1 / 002G2: For the second portion, mannitol (3.5 g) was added under stirring and the solution was set aside for physical observation and subsequent freeze-drying (pH 12.64). After approximately 24 hours the solution had not changed physically and the clear solution was subjected to freeze-drying for 24 hours. After freeze-drying the material appeared to be quite sticky indeed and it was extremely difficult to fill it into capsules. The stickiness could be a result of the corrosive nature of NaOH, due to the high pH of the solution (12.5) or simply due to the presence of mannitol. [Table 10] [Table 11]

[0185] In the next step, other surfactants were evaluated as solubilizers of arsenic trioxide. Further experiments of 1 were also carried out using increasing amounts of purified water and sodium carbonate instead of NaOH. Further experiments of 1 were also carried out adjusting the pH to 7-8 with NaOH. Another experiment was carried out to evaluate the effect of mannitol on the adhesive properties after lyophilization.

[0186] Experiment number L040 / 1 / 003 The purpose of this experiment was to perform the solubility of arsenic trioxide with poloxamer and sodium carbonate.

[0187] L040 / 1 / 003A: Solubility improvement using poloxamer In a beaker, 200 mg of poloxamer was dissolved in 100 mL of purified water under stirring (2 mg / mL solution). From this solution, 50 mL was taken and 50 mg of drug was added. The drug was found to be insoluble. Further addition of 50 mg of poloxamer did not dissolve the drug even after a 20 minute stirring step. [Table 12]

[0188] L040 / 1 / 003B: Increased solubility with increasing amount of purified water This experiment was similar to L040 / 1 / 002F. In a beaker, 1250 mg of sodium carbonate was added to 50 ml of purified water (25 mg of sodium carbonate / ml). To this solution was added 50 mg of arsenic trioxide drug under stirring, but no solubility of the drug was observed (pH 11.25). Addition of 100 mL of purified water also did not dissolve the drug. [Table 13]

[0189] Experiment L040 / 1 / 004 The aim of this experiment was to evaluate the effect of adjusting the pH to about 8 (using 6M HCl) on the adhesive properties after freeze-drying, using sodium hydroxide and a bulking agent (mannitol). Arsenic trioxide was dispersed in purified water and 12 mL of 3M NaOH was added under stirring until a clear solution was formed. The pH was adjusted to 7-8 using 6M HCl. Purified water was added to the above solution up to 500 ml and it was divided into two lots: Lot 1: L040 / 1 / 004A1: 250 mL was lyophilized for 24 hours. Lot 2: L040 / 1 / 004A2: 250 mL was mixed with mannitol and lyophilized for 24 hours. [Table 14] [Table 15]

[0190] Experiment L040 / 1 / 004B The aim of this experiment was to prepare Lyopremix for freeze-drying. Studies were carried out with sodium hydroxide in solid form with reduced amounts of purified water and with mannitol as a bulking agent. In a first step, arsenic trioxide and NaOH were dispersed in purified water and stirring was continued until a clear solution was formed. 6M HCl was added to this solution and it was subjected to freeze-drying for 24 hours. After 24 hours of freeze-drying, for batch L040 / 1 / 004A1, a white fluffy powder was observed. For L040 / 1 / 004A2, an off-white sticky material was observed, which was important to remove from the Petri dish. For L040 / 1 / 004B, a white fluffy powder was observed. Based on these experiments, it was concluded that the sticky nature of the material (Lyopremix) was due to mannitol in solution.

[0191] In the first step, lyophilized forms of arsenic trioxide and NaOH were added to pearlitol SD 200, sieved through #40 mesh (400 μm) and mixed for 10 minutes. In the next step, talc and magnesium stearate were sieved through #60 mesh (250 μm) and added to the material from the first step and mixed for 5 minutes. The final mixture was filled into size "0" hard gelatin capsule shells under a laminar airflow system. [Table 16]

[0192] The L040 / 1 / 004B batch was further processed with mannitol as a filler. [Table 17]

[0193] Experiment number L040 / 1 / 005 The purpose of this study was to evaluate the dissolution of a drug, e.g., arsenic trioxide, loaded into a "0" size hard gelatin capsule shell (equivalent to 10 mg). Even after 60 minutes, dissolution was found to be incomplete. [Table 18]

[0194] The next study was designed to use different surfactants in the formulation to improve dissolution.

[0195] In experiment L040 / 1 / 006, the study carried out was similar to L040 / 1 / 004B and was based on precipitation of the solution, and the amount of solvent (purified water) was optimized for 25 mg / ml arsenic trioxide. In experiment L040 / 1 / 007, studies were carried out with and without different surfactants to evaluate dissolution and differential scanning calorimetry (DSC) studies. For arsenic trioxide capsules, the aim was to prepare drug solutions (25 mg / mL arsenic trioxide) incorporating different surfactants.

[0196] In the first step, arsenic trioxide was dispersed in 64 mL of purified water. In the next step, 4 g of sodium hydroxide was added to the above step and the solubility of the drug was observed at pH 12.82. 6M HCl was added to this solution and the pH was observed to be 8.05. Purified water was added to this solution and the solution was divided into various portions (each portion contains 40 ml): L040 / 1 / 007: 40 ml of drug solution; L040 / 1 / 007A: 40 ml of drug solution to which 0.5 g of sodium lauryl sulfate has been added; and L040 / 1 / 007B: 40 ml of drug solution to which was added 0.5 g of Tween 80®.

[0197] Solutions L040 / 1 / 007 and L040 / 1 / 007A were analyzed by Differential Scanning Calorimetry (DSC) to assess the melting points. From the DSC study it is clear that there was no significant change in the melting points. [Table 19]

[0198] Experiment L040 / 1 / 008 The aim of the next experiment was to use two different concentrations of sodium lauryl sulfate for freeze-drying in a study similar to experiment L040 / 1 / 007. 160 mL of purified water was taken in a beaker, to which 10 g of arsenic trioxide and 10 g of NaOH were added and stirring was continued until a clear solution was formed (pH 12.38). 40 mL of 6M HCl was added to this solution under stirring (pH 8.04). Further, 200 mL of purified water was added to the above solution under stirring (pH 8.18). This solution was then divided into various portions (each portion containing 80 mL): Part 1: L040 / 1 / 008A: As solution. Part 2: L040 / 1 / 008E: 1 g of sodium lauryl sulfate was added to 80 ml of solution under stirring (nominal amount: 25 mg contains 10 mg of arsenic trioxide). Part 3: L040 / 1 / 008F: 0.2 g of sodium lauryl sulfate was added to 80 mL of stirred solution (nominal amount: 21 mg contains 10 mg of arsenic trioxide).

[0199] All solutions were then subjected to freeze-drying for 24 hours and samples were harvested after freeze-drying. [Table 20] [Table 21]

[0200] The actual yield of each batch was higher than the theoretical yield, which was attributed to the moisture uptake by the Lyopremix. Based on the quantitative values, the Lyopremix was mixed with the external granular material and filled into capsules. [Table 22]

[0201] Based on the above quantification, the following loading studies were performed. [Table 23] [Table 24] [Table 25]

[0202] Lyophilized forms of arsenic trioxide and NaOH (Lyopremix) were added to pearlitol SD 200, sieved through #40 mesh, and mixed for 10 minutes. Talc and magnesium stearate were sieved through #60 mesh, added to the above material, and mixed for 5 minutes. The powder was filled into size "2" capsules.

[0203] [Table 26]

[0204] From the above data, it is clear that complete dissolution was observed for all batches. In the next step, larger batch samples similar to L040 / 1 / 012B and all strengths 1 mg, 5 mg, 10 mg and 20 mg were filled. Based on batch no. L040 / 1 / 012B, a confirmation batch (batch no. L040 / 4 / 014) was manufactured in all strengths (1 mg, 5 mg, 10 mg and 20 mg). [Table 27] [Table 28]

[0205] In the next step, arsenic trioxide and sodium hydroxide pellets were dispersed in 480 ml of purified water and stirring was continued until a clear solution was formed. 120 mL of 6M HCl was added to the solution under stirring. 15 g of sodium lauryl sulfate was added to the solution under stirring. Further, 20 mL of purified water was added to the above solution. The solution was divided into two portions (L040 / 4 / 014A and L040 / 4 / 014B) and freeze-dried for about 30 hours. [Table 29] [Table 30]

[0206] In the next step, lyophilized forms of arsenic trioxide and NaOH (Lyopremix) were added to pearlitol SD 200, sieved through #40 mesh, and mixed for 10 minutes. Talc and magnesium stearate were sieved through #60 mesh, added to the above material, and mixed for 5 minutes. The final mixture, as well as the appropriate capsules and glass vials, were prepared as follows: [Table 31] [Table 32] [Table 33] [Table 34] [Table 35] [Table 36] [Table 37]

[0207] Pharmacokinetic analysis of a novel lyophilized formulation containing arsenic in dogs and comparison with control arsenic trioxide The objective of these studies was to determine the oral bioavailability and systemic exposure of novel arsenic-containing formulations utilizing lyophilization technology in dogs, a well-documented non-rodent species routinely used to estimate the pharmacokinetic properties of novel drugs and formulations in humans.

[0208] research design Groups of male dogs (n=3) were administered a formulation of arsenic trioxide (ARSENOX®) IV at 0.3 mg / kg, unformulated As2O3 (SV100) orally at a dose of 2 mg / dog, or a lyophilized As2O3 formulation (SV101) orally at a dose of 2 mg / dog. A fourth group of dogs was administered SV101 orally at 2 mg / dog for later confirmatory analysis. Blood samples were obtained from animals in group 1 pre-dose and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose, and from animals in groups 2, 3, and 4 pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose. Blood samples were immediately placed on wet ice and processed to plasma within 30 minutes of collection. Plasma samples were analyzed at QPS Netherlands BV for arsenic levels using an ICP-MS method with a lower limit of quantification (LLOQ) of 2.50 ng / mL. Individual time-concentration data were analyzed using WinNonlin TM Version 5.2.1 was used to calculate PK parameters for arsenic.

[0209] result After IV bolus administration of ARSENOX®, plasma levels of arsenic reached 146 ng / ml with a Tmax of 1.3 hours and a half-life (t 1 / 2 ) (Figure 1). The mean total body clearance was 226 mL / h / kg, and the mean Vss was 2734 mL / kg. After oral administration, SV100 showed a significant increase in oral bioavailability (F b%) showed very limited absorption of <10%. Oral absorption of SV101 (Group 3) was nearly identical to ARSENOX® (IV) with a Cmax of 182±34.5 ng / ml (for ARSENOX®, 146±17.6 ng / ml) and AUC0-last (h.ng / mL) of 1416±345 (for ARSENOX®, 1115±127), indicating complete oral absorption. These data were confirmed by repeated dosing of SV101 (Group 4), which produced nearly identical PK exposure parameters. No tolerability issues were identified during oral administration of As2O3.

[0210] conclusion Animals were administered As2O3 intravenously or as an oral formulation by a single dose. The study results showed that the absorption rate of arsenic and drug exposure in the SV101-treated group were significantly higher than that in the SV100 group. The complete oral absorption of As2O3 in the SV101-treated group was demonstrated by the nearly identical systemic exposure of arsenic compared to IV-administered ARSENOX®.

[0211] Characterization of pharmaceutical capsules containing lyophilized compositions containing arsenic The objective of these experiments was to characterize capsule formulations containing arsenic and summarize their physicochemical properties. The capsule sizes produced were 1 mg, 2 mg, 5 mg, 10 mg and 20 mg of lyopremix formulations containing arsenic. 4000 capsules were produced. The manufacturing process comprised (A) freeze-drying, and (B) mixing and lubrication steps. Figure 2 shows the manufacturing flow diagram for capsule creation.

[0212] (A) Freeze-drying The freeze-drying was carried out in three steps:

[0213] 1. Freeze After solubilization, the clear solution was placed in a freeze dryer set at a temperature of -40°C to freeze the formulation. [Table 38]

[0214] 2. Primary drying This step is also called the "sublimation" step. In this step, drying was carried out in the presence of a vacuum and at gradually increasing temperatures until the material was converted to a solid form. The process parameters for this step are tabulated below. [Table 39]

[0215] 3. Secondary drying The material after primary drying was dried again at optimized vacuum and temperature to remove bound water. [Table 40]

[0216] (B) Mixing and Lubrication The quantitative amount of Liopremix was estimated and the actual amount of Liopremix required per capsule was calculated as follows: Actual amount of Opremix per capsule, mg (A) = [(amount per capsule) x 100] / [quantity], amount of mannitol dispersed per capsule, mg (B) = theoretical amount of mannitol - [A - theoretical amount of Opremix], amount dispersed per batch = B x batch size

[0217] The excess amount of Lyopremix taken based on the actual amount was made up with mannitol as shown above. Lyopremix and mannitol were passed through an ASTM #40 mesh sieve and mixed by hand in a polyethylene bag for 10 minutes. The mixture was lubricated by hand in a polyethylene bag with magnesium stearate and talc pre-sieved through ASTM #60 mesh. The mixture was then filled into capsules according to the following details: [Table 41]

[0218] Physicochemical characterization The drug formulation was characterized for its physicochemical properties and evaluated comparatively with the raw material.

[0219] 1. Particle size analysis The API and final formulation were characterized for particle size distribution by a Malvern Mastersizer, and the data is shown in the table below. [Table 42]

[0220] A significant reduction in the PSD during the lyopremix stage is evident in the above data, which likely helped to improve the solubility of arsenic trioxide in the formulation. However, applicants do not wish to be bound by this theory or any scientific theory for that matter. It should be noted that the PSD of the final formulation also contains approximately 75% of other additional excipients.

[0221] 2. Polymorphism The final formulation was analyzed for API polymorphic form after processing to evaluate any polymorphic form change from the API. The intermediate stage (lyopremix) was also characterized by XRD diffractograms. From this study, it was concluded that there was no morphological change of API in the formulation and it was found to be stable at the intermediate stages of manufacture. The diffractograms are shown in Figures 3-6, which demonstrate that the same polymorphic form was found to be stable throughout the process and in the final formulation.

[0222] 3. Imaging with a Scanning Electron Microscope (SEM) Three samples, namely the simple API, the lyopremix and the final blend, were characterized for particle size and morphology characterization by SEM. The images are shown in Figure 7.

[0223] 4. FTIR Characterization of the API, lyopremix and final formulation by FTIR was performed. The spectra of the lyopremix and final formulation are comparable to the observed spectra of the API.

[0224] 5. Solubility studies According to the literature, arsenic trioxide is slightly soluble in cold water and insoluble in alcohol. Therefore, the solubility of the API and Lyopremix was tested in these media to evaluate their behavior and the results are presented below. [Table 43]

[0225] The results of the solubility study indicate that the solubility of the API was improved approximately 20-fold by the lyophilization method of the present invention. 6. Chemical properties of all strengths of drug formulations [Table 44]

[0226] 7. BET surface area measurement The surface areas of the API and Liopremix were measured using the BET method for surface area measurement. The specific surface area of ​​arsenic trioxide API is 0.05 m 2 The specific surface area of ​​the lyophilized composition or Lyopremix containing arsenic trioxide was measured to be 2.68 m 2 / g, a more than 50-fold increase in surface area.

[0227] Table 39 below provides surface area data for the API. Figure 8 provides a BET surface area plot for the API, which shows how 1 / [Q(Po / P-1)] depends on the relative pressure P / Po. [Table 45]

[0228] Table 40 below provides surface area data for Lyopremix. Figure 9 provides a BET surface area plot for Lyopremix, which shows how 1 / [Q(Po / P-1)] depends on the relative pressure P / Po. [Table 46]

[0229] Polymorphism studies showed that the API remained unchanged during the manufacturing process and in the final formulation indicating its stability. SEM images in Figure 7 show that the API particle size dramatically decreases during lyophilization. The final mixture contains other excipients and hence its size appears coarser. The chemical properties of all strengths of formulation, 1, 2, 5, 10, 20 mg capsules were found to meet and conform to the specifications of the final formulation. A significant improvement in dissolution was observed with the formulation compared to the API, which indicated a several-fold improvement in the solubility of arsenic trioxide in the formulation.

Claims

1. 1. A method for producing a freeze-dried composition containing arsenic (LCCA), comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 forming a solution; and (B) As 2 O 3 Freeze-drying the solution A method comprising:

2. As 2 O 3 The step of solubilizing the powder in an aqueous solvent comprises: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution 2. The method of claim 1, comprising:

3. The alkalizing agent is sodium hydroxide (NaOH), sodium carbonate (Na 2 CO 3 ), or a mixture thereof.

4. The amount of the alkalizing agent added is As 2 O 3 The method of claim 2, wherein the amount of the powder is about 10% to about 100%.

5. 3. The method of claim 2, wherein the acid comprises hydrochloric acid (HCl).

6. 6. The method of claim 5, wherein the HCl is about 6M HCl.

7. 3. The method of claim 2, wherein the acid is added to the vessel to adjust the pH to about 7.

2.

8. 3. The method of claim 2, wherein the surfactant comprises at least one of sodium lauryl sulfate; Tween 80 (registered trademark); beta cyclodextrin; poloxamer; and tocopheryl polyethylene glycol succinate (TPGS).

9. The surfactant is added to about 0.5% v / v to about 4.0% v / v, but As 2 O 3 The method of claim 2, wherein the concentration does not exceed about 50%.

10. The freeze-drying process: (A) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (B) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic.

2. The method of claim 1, comprising:

11. The freezing step comprises freezing the As at a temperature ranging from about -50°C to about 0°C. 2 O 3 11. The method of claim 10, comprising freezing the solution.

12. As 2 O 3 12. The method of claim 11, wherein the solution is frozen at about -40°C for at least about 6 hours.

13. The drying process is carried out under three conditions: (I) As 2 O 3 drying the product at at least one temperature ranging from about -40°C to about 50°C for a time ranging from about 5 minutes to about 500 minutes; (II) gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time period in the range of about 5 minutes to about 500 minutes, 2 O 3 wherein the at least one second temperature is higher than the at least one first temperature; and (III) The frozen As 2 O 3 Applying a vacuum to the product in the range of about 300 mTorr to about 1000 mTorr for a time period in the range of about 5 minutes to about 500 minutes. The method of claim 10, comprising at least one of:

14. The drying step comprises: 2 O 3 heating the product at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 Heating the product at -20°C and 500 mTorr for about 120 minutes; 2 O 3 heating the product at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product at about 10° C. and about 500 mTorr for about 60 minutes; and 2 O 3 11. The method of claim 10, comprising heating the product at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

15. The drying step comprises: 2 O 3 heating the product to about -30°C and about 800 mTorr over about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 heating the product to about -20°C and about 500 mTorr over about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about -5°C and about 500 mTorr over about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about 10° C. and about 500 mTorr over about 120 minutes and holding at about 10° C. and about 500 mTorr for about 60 minutes; and removing As from the previous step. 2 O 3 11. The method of claim 10, comprising heating the product to about 25° C. and about 500 mTorr for about 60 minutes and holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

16. A composition comprising a freeze-dried composition containing arsenic (LCCA).

17. 17. The composition of claim 16, further comprising at least one filler and at least one lubricant.

18. The composition comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 forming a solution; (B) As 2 O 3 lyophilizing the solution to produce the lyopremix; (C) The lyopremix is ​​sieved and freeze-dried. 2 O 3 forming a powder; (D) optionally, suspending at least one filler in said lyophilized As 2 O 3 adding to the powder; (E) optionally adding one or more lubricants to the lyophilized As 2 O 3 In addition to the powder, the As 2 O 3 forming an oral formulation of 20. The composition of claim 17, produced by a process comprising:

19. As 2 O 3 The step of solubilizing the powder in an aqueous solvent comprises: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution 20. The composition of claim 18, comprising:

20. The alkalizing agent is sodium hydroxide (NaOH), sodium carbonate (Na 2 CO 3 20. The composition of claim 19, comprising:

21. The amount of the alkalizing agent added is As 2 O 3 20. The composition of claim 19, which is about 10% to about 100% by weight of powder.

22. 20. The composition of claim 19, wherein the acid comprises hydrochloric acid (HCl).

23. 23. The composition of claim 22, wherein the HCl is about 6M HCl.

24. 20. The composition of claim 19, wherein the acid is added to the vessel to adjust the pH to about 7.

2.

25. 20. The composition of claim 19, wherein the surfactant comprises at least one of: sodium lauryl sulfate; Tween 80 (registered trademark); beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS).

25. The surfactant is added to about 0.5% v / v to about 4.0% v / v, but As 2 O 3 20. The composition of claim 19, wherein the concentration does not exceed about 50%.

26. The freeze-drying process: (A) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (B) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic.

20. The composition of claim 18, comprising:

27. The freezing step comprises freezing the As at a temperature ranging from about -50°C to about 0°C. 2 O 3 27. The composition of claim 26, comprising freezing the solution.

28. As 2 O 3 28. The composition of claim 27, wherein the solution is frozen at about -40°C for at least about 6 hours.

29. The drying process is carried out under three conditions: (I) As 2 O 3 drying the product at at least one temperature ranging from about -40°C to about 50°C for a time ranging from about 5 minutes to about 500 minutes; (II) gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time period in the range of about 5 minutes to about 500 minutes, 2 O 3 wherein the at least one second temperature is higher than the at least one first temperature; and (III) The frozen As 2 O 3 Applying a vacuum to the product in the range of about 300 mTorr to about 1000 mTorr for a time period in the range of about 5 minutes to about 500 minutes.

27. The composition of claim 26, comprising at least one of:

30. The drying step comprises: 2 O 3 heating the product at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 Heating the product at -20°C and 500 mTorr for about 120 minutes; 2 O 3 heating the product at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product at about 10° C. and about 500 mTorr for about 60 minutes; and 2 O 3 27. The composition of claim 26, comprising heating the product at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

31. The drying step comprises: 2 O 3 heating the product to about -30°C and about 800 mTorr over about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 heating the product to about -20°C and about 500 mTorr over about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about -5°C and about 500 mTorr over about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about 10° C. and about 500 mTorr over about 120 minutes and holding at about 10° C. and about 500 mTorr for about 60 minutes; and removing As from the previous step. 2 O 3 27. The composition of claim 26, comprising heating the product to about 25° C. and about 500 mTorr for about 60 minutes and holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

32. 18. The composition of claim 17, wherein the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.

33. 17. The composition of claim 16, wherein the composition is a controlled release, oral, solid, composition.

34. 17. The composition of claim 16, which is encapsulated.

35. Arsenic or freeze-dried arsenic trioxide (As 2 O 3 1. A method for producing an oral pharmaceutical formulation comprising a lyophilized composition comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 forming a solution; (B) As 2 O 3 lyophilizing the solution to produce the lyopremix; (C) The lyopremix is ​​sieved and freeze-dried. 2 O 3 forming a powder; (D) optionally, suspending at least one filler in said lyophilized As 2 O 3 adding to the powder; (E) optionally adding one or more lubricants to the lyophilized As 2 O 3 In addition to the powder, the As 2 O 3 forming an oral formulation of A method comprising:

36. As 2 O 3 The step of solubilizing the powder in an aqueous solvent comprises: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution 36. The method of claim 35, comprising:

37. The alkalizing agent is sodium hydroxide (NaOH), sodium carbonate (Na 2 CO 3 37. The method of claim 36, comprising:

38. The amount of the alkalizing agent added is As 2 O 3 The method of claim 36, wherein the amount of the powder is about 10% to about 100%.

39. 37. The method of claim 36, wherein the acid comprises hydrochloric acid (HCl).

40. 40. The method of claim 39, wherein the HCl is about 6M HCl.

41. 37. The method of claim 36, wherein the acid is added to the vessel to adjust the pH to about 7.

2.

42. 37. The method of claim 36, wherein the surfactant comprises at least one of sodium lauryl sulfate; Tween 80 (registered trademark); beta cyclodextrin; poloxamer; and tocopheryl polyethylene glycol succinate (TPGS).

43. The surfactant is added to about 0.5% v / v to about 4.0% v / v, but As 2 O 3 37. The method of claim 36, wherein the concentration does not exceed about 50%.

44. The freeze-drying process: (A) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (B) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic.

36. The method of claim 35, comprising:

45. The freezing step comprises freezing the As at a temperature ranging from about -50°C to about 0°C. 2 O 3 45. The method of claim 44, comprising freezing the solution.

46. As 2 O 3 46. ​​The method of claim 45, wherein the solution is frozen at about -40°C for at least about 6 hours.

47. The drying process is carried out under three conditions: (I) As 2 O 3 drying the product at at least one temperature ranging from about -40°C to about 50°C for a time ranging from about 5 minutes to about 500 minutes; (II) gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time period in the range of about 5 minutes to about 500 minutes, 2 O 3 wherein the at least one second temperature is higher than the at least one first temperature; and (III) The frozen As 2 O 3 Applying a vacuum to the product in the range of about 300 mTorr to about 1000 mTorr for a time period in the range of about 5 minutes to about 500 minutes.

45. The method of claim 44, comprising at least one of:

48. The drying step comprises: 2 O 3 heating the product at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 Heating the product at -20°C and 500 mTorr for about 120 minutes; 2 O 3 heating the product at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product at about 10° C. and about 500 mTorr for about 60 minutes; and 2 O 3 45. The method of claim 44, comprising heating the product at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

49. The drying step comprises: 2 O 3 heating the product to about -30°C and about 800 mTorr over about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 heating the product to about -20°C and about 500 mTorr over about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about -5°C and about 500 mTorr over about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about 10° C. and about 500 mTorr over about 120 minutes and holding at about 10° C. and about 500 mTorr for about 60 minutes; and removing As from the previous step. 2 O 3 45. The method of claim 44, comprising heating the product to about 25°C and about 500 mTorr over a period of about 60 minutes and holding at about 25°C and about 500 mTorr for a period of time ranging from about 180 minutes to about 300 minutes.

50. 36. The method of claim 35, wherein the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.

51. 36. The method of claim 35, further comprising filling a capsule with the oral formulation.

52. 1. A pharmaceutical composition in solid dosage form suitable for oral administration, comprising a lyophilized composition comprising arsenic.

53. 53. The pharmaceutical composition of claim 52, further comprising at least one filler and at least one lubricant.

54. The composition comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 forming a solution; (B) As 2 O 3 lyophilizing the solution to produce the lyopremix; (C) The lyopremix is ​​sieved and freeze-dried. 2 O 3 forming a powder; (D) optionally, suspending at least one filler in said lyophilized As 2 O 3 adding to the powder; (E) optionally adding one or more lubricants to the lyophilized As 2 O 3 In addition to the powder, the As 2 O 3 forming an oral formulation of 53. The pharmaceutical composition of claim 52, produced by a process comprising:

55. As 2 O 3 The step of solubilizing the powder in an aqueous solvent comprises: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution 55. The pharmaceutical composition of claim 54, comprising:

56. The alkalizing agent is sodium hydroxide (NaOH), sodium carbonate (Na 2 CO 3 56. The pharmaceutical composition of claim 55, comprising:

57. The amount of the alkalizing agent added is As 2 O 3 56. The pharmaceutical composition of claim 55, which is about 10% to about 100% by weight of the powder.

58. 56. The pharmaceutical composition of claim 55, wherein the acid comprises hydrochloric acid (HCl).

59. 59. The pharmaceutical composition of claim 58, wherein the HCl is about 6M HCl.

60. 56. The pharmaceutical composition of claim 55, wherein the acid is added to the vessel to adjust the pH to about 7.

2.

61. 56. The pharmaceutical composition of claim 55, wherein the surfactant comprises at least one of: sodium lauryl sulfate; Tween 80 (registered trademark); beta cyclodextrin; poloxamer; tocopheryl polyethylene glycol succinate (TPGS).

62. The surfactant is added to about 0.5% v / v to about 4.0% v / v, but As 2 O 3 56. The pharmaceutical composition of claim 55, wherein the concentration does not exceed about 50%.

63. The freeze-drying process: (A) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (B) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic.

55. The pharmaceutical composition of claim 54, comprising:

64. The freezing step comprises freezing the As at a temperature ranging from about -50°C to about 0°C. 2 O 3 64. The pharmaceutical composition of claim 63, comprising freezing the solution.

65. As 2 O 3 65. The pharmaceutical composition of claim 64, wherein the solution is frozen at about -40°C for at least about 6 hours.

66. The drying process is carried out under three conditions: (I) As 2 O 3 drying the product at at least one temperature ranging from about -40°C to about 50°C for a time ranging from about 5 minutes to about 500 minutes; (II) gradually increasing the temperature from at least one first temperature in the range of about -40°C to about 50°C to at least one second temperature in the range of about -40°C to about 50°C for a time period in the range of about 5 minutes to about 500 minutes, 2 O 3 wherein the at least one second temperature is higher than the at least one first temperature; and (III) The frozen As 2 O 3 Applying a vacuum to the product in the range of about 300 mTorr to about 1000 mTorr for a time period in the range of about 5 minutes to about 500 minutes.

64. The pharmaceutical composition of claim 63, comprising at least one of:

67. The drying step comprises: 2 O 3 heating the product at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 Heating the product at -20°C and 500 mTorr for about 120 minutes; 2 O 3 heating the product at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product at about 10° C. and about 500 mTorr for about 60 minutes; and 2 O 3 64. The pharmaceutical composition of claim 63, comprising heating the product at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

68. The drying step comprises: 2 O 3 heating the product to about -30°C and about 800 mTorr over about 60 minutes and holding at about -30°C and about 800 mTorr for about 60 minutes; 2 O 3 heating the product to about -20°C and about 500 mTorr over about 60 minutes and holding at about -20°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about -5°C and about 500 mTorr over about 300 minutes and holding at about -5°C and about 500 mTorr for about 120 minutes; 2 O 3 heating the product to about 10° C. and about 500 mTorr over about 120 minutes and holding at about 10° C. and about 500 mTorr for about 60 minutes; and removing As from the previous step. 2 O 3 64. The pharmaceutical composition of claim 63, comprising heating the product to about 25° C. and about 500 mTorr for about 60 minutes and holding at about 25° C. and about 500 mTorr for a time period ranging from about 180 minutes to about 300 minutes.

69. 55. The pharmaceutical composition of claim 54, wherein the filler comprises mannitol; and / or the one or more lubricants comprise talc and / or magnesium stearate.

70. 53. The pharmaceutical composition of claim 52, wherein the composition is a controlled release, oral, solid, pharmaceutical composition.

71. 53. The pharmaceutical composition of claim 52, encapsulated.

72. 53. A capsule comprising about 1 mg of the pharmaceutical composition of claim 52.

73. 53. A capsule comprising about 5 mg of the pharmaceutical composition of claim 52.

74. 53. A capsule comprising about 10 mg of the pharmaceutical composition of claim 52.

75. 53. A capsule comprising about 20 mg of the pharmaceutical composition of claim 52.

76. 53. A kit comprising the pharmaceutical composition of claim 52 and instructions for its use.

77. 1. A method for orally administering to a subject a pharmaceutical composition comprising a lyophilized composition comprising arsenic, the method comprising the steps of providing the pharmaceutical composition and orally administering the pharmaceutical composition to the subject.

78. 1. A method of treating cancer in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a lyophilized composition comprising arsenic.

79. 79. The method of claim 78, wherein the cancer is a hematopoietic malignancy.

80. The method of claim 79, wherein the hematopoietic tumor is at least one of acute myeloid leukemia; acute nonlymphocytic leukemia; myeloblastic leukemia, promyelocytic leukemia; chronic myelomonocytic leukemia; monocytic leukemia; erythroleukemia; acute neutrophilic leukemia; myelodysplastic syndrome; acute promyelocytic leukemia; chronic lymphocytic leukemia; chronic myelogenous leukemia; hairy cell leukemia; myeloproliferative neoplasm; Hodgkin's lymphoma; non-Hodgkin's lymphoma; myeloma; giant cell myeloma; indolent myeloma; localized myeloma; multiple myeloma; plasma cell myeloma; sclerosing myeloma; solitary myeloma; smoldering multiple myeloma; nonsecretory myeloma; osteosclerosing myeloma; plasma cell leukemia; solitary plasmacytoma; and extramedullary plasmacytoma.

81. 80. The method of claim 79, wherein the hematopoietic tumor is acute promyelocytic leukemia (APL).

82. 82. The method of claim 81, wherein the APL is newly diagnosed APL.

83. The method of claim 81, wherein the APL is relapsed or refractory APL.

84. 81. The method of claim 80, wherein the myeloproliferative neoplasm is one of myelofibrosis polycythemia vera and essential thrombocythemia.

85. 79. The method of claim 78, wherein the pharmaceutical composition is administered daily.

86. 79. The method of claim 78, wherein the pharmaceutical composition is administered in a single dosage ranging from about 1 mg to about 50 mg.

87. 79. The method of claim 78, wherein the pharmaceutical composition is administered in a single dosage ranging from about 0.1 mg / kg body weight to about 0.3 mg / kg body weight.

88. 79. The method of claim 78, wherein the patient has previously been treated or is currently being treated with chemotherapy and / or radiation.

89. 90. The method of claim 88, further comprising administering to said patient one or more chemotherapeutic agents.

90. 89. The method of claim 88, wherein said chemotherapeutic agent is administered before, after or simultaneously with said pharmaceutical composition.

91. 1. A method for increasing the surface area of ​​an original API powder containing arsenic trioxide by about 5 to about 80 times: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 Forming a solution comprising: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution and (B) As 2 O 3 lyophilizing the solution, comprising: (V) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (VI) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic. Process including A method comprising:

92. 1. A method for increasing the solubility of arsenic trioxide powder in water or alcohol by about 2-fold to about 30-fold, comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 Forming a solution comprising: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution and (B) As 2 O 3 lyophilizing the solution, comprising: (V) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (VI) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic. Process including A method comprising:

93. 1. A method for increasing the dissolution of a pharmaceutical composition containing arsenic by at least 5-fold over a parent API containing arsenic trioxide, comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 Forming a solution comprising: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution and (B) As 2 O 3 lyophilizing the solution, comprising: (V) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (VI) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic. Process including A method comprising:

94. 1. A method for providing an oral bioavailability of arsenic to a subject that ranges from about 50% to about 100% of the bioavailability of intravenous administration of a pharmaceutical composition comprising arsenic, comprising: (A)As 2 O 3 The powder was solubilized in an aqueous solvent to obtain As 2 O 3 Forming a solution comprising: (I) As in vessels with or without stirring and with or without added water 2 O 3 adding an alkalizing agent to the powder to achieve a pH of about 12 or greater; (II) adding acid to the vessel, with or without stirring and with or without the addition of water, to adjust the pH to about 7 to about 8; (III) optionally adding a surfactant to the vessel, with or without stirring and with or without the addition of water; and (IV) Add water to the vessel, with or without stirring as appropriate, and add As 2 O 3 Producing a solution and (B) As 2 O 3 lyophilizing the solution, comprising: (V) As 2 O 3 Freeze the solution and freeze As 2 O 3 Producing a product; and (VI) As 2 O 3 drying the product to produce a freeze-dried composition comprising said arsenic. Process including A method comprising:

95. 17. The composition of claim 16, wherein the lyophilized composition comprising arsenic comprises particles in the D(90) size range of about 2 μm to 10 μm.

96. 17. The composition of claim 16, wherein the lyophilized composition comprising arsenic comprises particles having a D(90) size that is about 10 to about 50 times smaller than the particle size of the original API powder comprising arsenic trioxide.

97. The freeze-dried composition containing arsenic is about 0.5 m 2 / g~5m 2 17. The composition of claim 16, comprising particles having a BET surface area in the range of 1 / g.

98. 17. The composition of claim 16, wherein the lyophilized composition comprising arsenic comprises particles having a BET surface area that is about 2 to about 80 times greater than the surface area of ​​the original API powder comprising arsenic trioxide.

99. 17. The composition of claim 16, wherein the lyophilized composition containing arsenic is about 2 to about 30 times more soluble in cold water or alcohol than the original API powder containing arsenic trioxide.

100. 17. The composition of claim 16, wherein the lyophilized composition comprising arsenic is soluble in cold water or alcohol in the range of about 4 g / 100 g to about 60 g / 100 g of lyophilized composition to cold water or alcohol.

101. 53. The pharmaceutical composition of claim 52, wherein the dissolution of the pharmaceutical composition is about 5-fold to about 15-fold that of the original API powder containing arsenic trioxide as measured by ICP-OES.

102. Weight of 100 units; total weight of composition is 100 units: (I) a lyophilized composition comprising arsenic in an amount to provide 10 units of arsenic trioxide and 5 units of sodium lauryl sulfate; (II) mannitol in an amount of 73 units; (III) talc in an amount of 1; and (IV) magnesium stearate in an amount of 1 mg 16. An oral dosage form in the form of a capsule comprising:

103. 102. The capsule of claim 101, wherein the capsule weighs 10 mg, 50 mg, 100 mg or 200 mg.

Citation Information

Cited By

  • Active energy ray-curable ink, method for producing same, and printed matter

    WO2024202482A1